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Thesis Description 
Chapter 1 is an overview of the pathophysiology of liver ischaemia reperfusion 
injury and the various molecular pathways involved in the manifestation of this 
injury. 
Chapter 2 is a review of the various therapeutic modalities used to ameliorate liver 
ischaemia reperfusion injury with a special emphasis on antioxidant therapy and N-
acetylcysteine 
Chapter 3 reviews the role of glycine a nonessential amino acid and its application 
to liver ischaemia reperfusion.  
Chapter 4 describes the various animal groups and materials and methods used in 
the various studies in this thesis. 
Chapter 5 summarizes the experimental findings and effects of intravenous glycine 
on hepatic haemodynamics, liver microcirculation and portal blood flow following 
liver IRI. 
Chapter 6 summarizes the experimental findings and effects of intravenous glycine 
on Cytokine expression and liver function tests following liver IRI 
Chapter 7 describes the effect of intravenous glycine on bile flow and the 
application of proton nuclear magnetic resonance (
1HNMR) spectroscopy in 
analysing the changes in bile composition following liver IRI 
Chapter 8 investigates the effect of prophylactically administered N-acetylcysteine 
on liver IRI in patients undergoing elective liver resection within a randomised 
controlled trial 
Chapter 9 is a general discussion of the thesis and conclusions with plans for further 
research based upon the findings of this thesis    9
Abstract 
Liver Ischaemia Reperfusion Injury (IRI) leads to production of reactive oxygen 
species and cytokines, which affects hepatocellular function following liver resection 
and transplantation. 
This thesis examines 2 hypotheses: 
1)  The role of intravenous glycine in amelioration of liver IRI in a in vivo animal 
model of partial lobar liver IRI.  
2)  Does prophylactically administered N-acetylcysteine prevent liver IRI in 
patients undergoing elective liver resection.  
Materials and Methods 
1)  A rabbit model of hepatic lobar IRI was used to evaluate glycine. 3 groups 
(n=6) Sham group (laparotomy alone), ischaemia reperfusion (I/R) group (1 
hour ischaemia and 6 hours of reperfusion), and glycine I/R group (IV glycine 
5 mg/kg prior to the I/R protocol) were used. Portal blood flow, bile flow and 
bile was analysed by H
1NMR spectroscopy. Hepatic microcirculation, 
intracellular tissue oxygenation, serum TNFα, IL-8, ALT, AST were measured 
at 1, 2, 4 and 6 hours following reperfusion.  
2)  A randomised double blind clinical trial was conducted to assess the effect of 
NAC on liver IRI following liver resections. The main outcomes were: 
morbidity and mortality, ICAM-1 expression in liver tissue, liver function tests. 
Patients were randomised to receive NAC as IV infusion (NACG) or a placebo 
group (PG) which received 5% dextrose only. Immunohistochemistry for 
ICAM-1 was carried out on perioperative liver biopsies. 
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Results 
1)  Glycine normalised the bile flow, reduced phosphatidylcholine shedding, 
lactate surge, and stimulated bile acid, pyruvate, glucose and acetoacetate 
release. Glycine improved portal blood flow, hepatic microcirculation by the 
2
nd hour, and hepatic intracellular tissue oxygenation by the 4
th hour of 
reperfusion. Glycine ameliorated serum TNF at 1, 2 and 4 hours and serum Il-
8, AST and ALT up to 6 hours post reperfusion as compared to the I/R alone 
group. 
2)  Of the 43 patients, 15 received NAC, 16 were randomised to the PG, 12 were 
excluded due to inoperable tumours. Serum ALT was reduced in NACG 
(p=0.001), while serum ALP was higher in the NACG (p=0.003). ICAM-1 
expression was up-regulated in 6/16 patients in the PG and in 3/15 patients in 
NACG. ICAM-1 was down-regulated in 1/15 patients in the NACG and none 
in the PG, the difference was not significant. 
Conclusions 
1)  Glycine ameliorated liver IRI, improved bile flow and composition. 
2) NAC  ameliorated parenchymal liver injury and enhanced liver regeneration in 
patients undergoing elective liver resection.  
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Ischaemia reperfusion injury in the liver: literature review 
and current concepts 
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1.1 Introduction 
Restoration of blood flow to an ischemic organ is essential to prevent irreversible 
cellular injury. However, reperfusion itself augments tissue injury already caused by 
ischaemia alone(68;386), which if severe enough may result in systemic 
inflammatory response syndrome or multiple organ dysfunction 
syndrome(280).Cellular damage after reperfusion of previously viable ischaemic 
tissues is thus defined as ischaemia reperfusion injury (IRI)(68). 
1.2 The clinical relevance of ischaemia reperfusion injury 
IRI is a major determinant in affecting the outcome in a variety of human disease 
processes including cerebrovascular accidents (stroke), myocardial infarction, 
coronary artery bypass surgery, organ transplantation, liver resection, haemorrhagic 
shock with fluid resuscitation following major trauma, and limb revascularization 
(374). IRI is also associated with chronic rejection due to arteriosclerosis caused by 
the injury (118). It is also one of the important factors for nonfunction of 
microvascular flaps as well as necrosis of adipocutaneous and musculoskeletal flaps. 
Acute organ failure following IRI is a well recognised complication in a number of 
organs including brain(43) ,heart(126), kidney(296), gastrointestinal tract(298), and 
liver(250).  
In the liver this form of injury is a common sequel following complex liver resection 
and liver transplantation(32;168). In general, three types of ischaemic liver injury is 
clinically seen:  
1) Cold ischaemia, seen in context of organ transplantation and graft preservation. 
2) Warm ischaemia seen during liver transplantation, shock and liver resectional 
surgery   20
3) Rewarming ischaemia typically seen during and following graft implantation 
Although liver transplantation provides effective therapy for most forms of acute and 
chronic liver failure, IRI, inherent to every transplantation is the main cause of both 
initial poor function (10%-30%) and primary non function(<5%) of the liver 
allograft.(66; 374). Organ shortage has led many centres to expand their criteria for 
acceptance of marginal donors like steatotic livers, small for size grafts, nonheart 
beating donors and aged donors (>70 years). Liver IRI is the primary factor affecting 
graft dysfunction seen in these marginal donors(56).  
Liver resection is the gold standard for treatment of colorectal liver 
metastases(125;325). Newer chemotherapeutic agents have provided the option of 
curative liver resection in patients previously deemed unresectable(244). Thus 
increasing number of patients are now eligible for liver surgery despite advanced 
age, fatty liver disease, large tumours and preoperative chemotherapy.Hepatic 
steatosis affects 25% of the population and is associated with impaired 
microcirculation and poor liver function. Liver IRI in this group of patients further 
increases the morbidity associated with major liver surgery(65;66). 
Liver IRI has been known to affect liver regeneration after hepatectomy(127). 
Following major liver resection or living related/ marginal graft liver transplantation, 
the ability of the liver to regenerate is crucial to maintain liver function. The failure 
of a partial liver to regenerate is considered a critical contributing factor in post 
surgical primary liver dysfunction and liver failure(66). Impaired liver regeneration 
and liver dysfunction has been directly linked to the extent and severity of liver 
IRI(65;66).   21
Thus limiting the extent of liver IRI may provide the key to make liver surgery safer 
especially for these high risk patients and improve the outcome of non heart beating, 
older and fatty donors in liver transplantation. 
1.3 Pathophysiology of ischaemia reperfusion injury 
Cellular effects of ischaemia are summarized in table 1.1. 
The process of cell death by ischaemia has been studied for many years and various 
sequences of events that can lead to cell death have been suggested (320) (51). In 
aerobic cells the energy necessary to maintain cell integrity is supplied by the 
mitochondrial system through complete reduction of oxygen to water with the 
concomitant production of ATP through oxidative phosphorylation (236;285).  
When oxygen supply to cells becomes insufficient by ischaemia or hypoxia, 
mitochondrial respiratory chain function alters because there is no final acceptor of 
electrons and the reduction/oxidation (redox) state of the mitochondrial enzymes 
becomes reduced(148). This causes inhibition of the mitochondrial ATP synthase 
with the subsequent reduction of oxidative phosphorylation(148). As a result a swift 
decrease of the stored energy-rich phosphates (ATP) occurs in the tissues as 
metabolic processes continue while oxidative phosphorylation ceases(266;351). 
Reduction of cellular ATP causes disturbances of membrane ion translocation by 
inhibition of the ATP-dependent sodium (Na
+)/potassium (K
+) ATPase, resulting in 
sodium influx and intracellular sodium accumulation with cell swelling and 
death(265). 
Intracellular calcium accumulation is strongly implicated in the development of 
ischaemic injury and is thought to be a crucial step in the transition to irreversible 
damage(324;392). It occurs secondary to calcium release from the intracellular stores 
and inhibition of the ATP-dependent calcium pumps in the plasma membrane and   22
endoplasmic reticulum(324;392). The increased cytosolic calcium causes activation 
of cell membrane phospholipases resulting in phospholipid degradation and cell 
membrane disruption(28) (269). Calcium also activates tissue proteases such as 
xanthine dehydrogenase enhancing its conversion to xanthine oxidase (XO) which 
play a significant role in oxygen free radical production and reperfusion injury 
(83;184). 
Table 1.1: Cellular effects of ischaemia 
 
Altered  Membrane Potential 
Altered Ion Distribution ( ↑ intracellular Ca
+2 /Na
+2) 
Cellular Swelling 
Cytoskeletal  Disorganization 
↑ Hypoxanthine 
↓ Adenosine 5 –Triphosphate (ATP) 
↓ Phosphocreatinine 
↓ Glutathione 
Cellular Acidosis 
  
 Key:  ↑=increased, ↓= decreased, Ca
+2 = calcium, Na
+2= sodium 
1.4 Phases of liver ischaemia reperfusion injury 
I/R induced liver injury occurs in a biphasic manner (184). Which are as follows: 
1)  Early Phase: which occurs within 1-4 hours following reperfusion and is 
characterised by Kupffer cell(KC) and Polymorphonuclear leucocyte (PMN) 
activation(82), increased  production of Nitric oxide(NO) by liver mitochondria 
and KCs (230;364), activation  of complement cascade and production of C5a 
by proteolytic cleavage(185) and generation of ROS such as Superoxide (O2
-),   23
hydrogen peroxide (H2O2) and/or hydroxyl radical (251;273). This early phase 
injury occurs in a PMN independent manner and is mediated  by ROS 
generated upon reperfusion (114;184;273). Thus the early phase initiated the 
signal transduction processes which promotes neutrophil influx in the 
liver(71;265)  
2)  Late Phase: which occurs between 4-24 hours following reperfusion and is 
characterised by PMN influx into the post ischemic liver and organ injury 
(187;194;351). These neutrophils are primed and activated during the early 
phase (71;314). The activated neutrophils a) adhere to endothelial cells and 
hepatocytes and generate ROS and release proteases which damages 
endothelial and parenchymal cells; b) obstructs hepatic sinusoidal blood flow 
leading to hepatic hypoperfusion (no reflow) (187). The activated neutrophils 
induced cellular injury is mediated by :  
a)  activation of NADPH oxidase(13;85)  
b)  induction of NOS (54;55) 
c)  release of products of arachidonic acid metabolism (i.e. leukotrienes, 
eicosanoids) and proteolytic enzymes (i.e. elastase, 
metalloproteinases)(414). 
This initiates rapid oxygen uptake known as respiratory burst (13;414) in which 
superoxide anion radicals (O2
-) and NO is produced(54). These react together to 
produce (H2O2) and peroxynitrite (ONOO
-) both of which are highly cytotoxic(20). 
1.5 Microcirculatory failure in liver ischaemia reperfusion injury 
The crucial role of microcirculatory impairment as a determinant of tissue viability 
after hepatic I/R has been investigated (208;340;394). Study of temporal and spatial 
microvascular changes with I/R using intravital microscopy showed two distinct   24
pathophysiologic mechanisms as key components of reperfusion injury. These 
mechanisms are primary sinusoidal perfusion failure ‘’no reflow’’(147) and ‘’reflow 
paradox’’ (292;320). 
In no reflow phenomenon, initially there is sinusoidal perfusion followed by 
progressive stasis and reduction of the sinusoidal flow (147). In reflow paradox 
phenomenon, reflow induces impairment of the microcirculation and tissue damage 
rather than improvement of the microcirculation and tissue function (402). 
The severity of the sinusoidal perfusion failure is dependent on the ischaemia 
time(187) .This sinusoidal impairment is paralleled with the changes in hepatic tissue 
oxygenation, hepatocellular integrity, and parenchymal function (340).This supports 
the major contribution of sinusoidal impairment to the reperfusion injury by 
increasing the hypoxic conditions during reperfusion(402). 
Several mechanisms contribute to the no reflow phenomena, including narrowing of 
the sinusoid lumens by endothelial cell swelling(60) secondary to ischaemia-induced 
ATP deficiency and the consequent failure of ion transport through the cell 
membrane(187;291). A significant reduction of leukocyte velocity with subsequent 
stasis and intrasinusoidal plugging has been suggested as a hindrance for blood 
perfusion (404). 
Apart from sinusoidal no reflow, reperfusion of microvessels is paradoxically 
associated with additional injury which is termed the ‘’reflow paradox’’ (187;404). 
Reflow paradox is closely linked with the inflammatory response characterised by a 
network of intercellular reactions which includes leukocyte, endothelial cells, and 
tissue cells (37;250). The role of leukocyte has been confirmed by the observation 
that the degree of leukocyte infiltration of the reperfused tissue correlates with   25
postoperative liver function impairment and hepatocyte injury (187;194). Also, in 
neutropenic animals there is a substantial decrease in the severity of I/R injury (187) 
Along with these chain of events Kupffer cells (KC) and neutrophils are activated, 
which produce inflammatory cytokines (71) and reactive oxygen species(ROS)   
further aggravating hepatic injury(347). 
1.6 Role of Kupffer cells, Neutrophils and Platelets in liver ischaemia 
reperfusion injury 
1.6.1: Kupffer Cells  
The pathogenesis of hepatic IRI, is initiated by activation of KC during ischaemia 
and initial stages of reperfusion (15;192;251;348). Activation of KC produces 
morphologic changes, which causes them to protrude into the sinusoids contributing 
to the reduction of blood flow within the sinusoidal lumen(47;249;348). Activated 
KC release proinflammatory (TNF, IL-1,IL-8, IL-6) and anti-inflammatory 
mediators (IL-10, IL-13) ,  as well as ROS which  appears to play a pivotal role in 
the inflammatory response during hepatic IRI (72;192;249;389). Thus KC 
modulation could potentially attenuate or aggravate IR induced organ injury 
1.6.2: Neutrophils 
Neutrophils are activated by the ROS and proinflammatory mediators released 
during reperfusion, and activated neutrophils further augment the IR injury by 
release of ROS and several proteases(243;388). 
Neutrophil recruitment during reperfusion and their adhesion to endothelial cells 
(EC) is mediated by the interaction between selectins and integrins expressed in the 
neutrophil membrane, and intercellular adhesion molecules (ICAM) expressed on 
EC.(388). I/R increases ICAM-1 expression  in hepatic EC probably through TNF 
and IL-1 synthesis which has been associated with acute liver rejection, while   26
neutralization of ICAM-1 reduces the severity of IRI(116;232;402). More recently T 
cells and NK-T cells have also been proposed to play an important role in hepatic 
IRI.(234). Resident lymphocytes within the liver can alter inflammation through the 
secretion of soluble mediators such as cytokines or through cognate interactions in an 
antigen dependent manner. Expression of these mediators will then result in the 
recruitment of more lymphocytes and neutrophils(45). 
1.6.3: Platelets 
Platelets adhere to the hepatic sinusoids and induce programmed EC death upon 
reperfusion of transplanted organs(353). Platelets also synthesize several factors 
(cytokines, TGF-β, serotonin, and calpain) which play an important role in liver I/R 
and regeneration (245). Platelet derived serotonin has been shown to promote tissue 
repair after normothermic hepatic ischaemia in mice(286). In human platelets , 
calpain activation is dependent on fibrinogen binding to integrin and subsequent 
platelet aggregation suggesting a role for this protease in regulation of post 
aggregation responses(333). Platelets also produce NO that leads to the production of 
peroxynitrite which is a potent inductor of programmed cell death in EC(150;340). 
1.7 Role of cytokines in liver ischaemia reperfusion injury 
Cytokines play an important role in liver IRI, both by initiating and sustaining the 
inflammatory response as well as modulating it’s severity (351;388). Cytokines due 
to their ability to act in a autocrine, paracrine, and humoral manner not only initiates 
and maintains the inflammatory response (351), but also induce production of other 
inflammatory mediators like other cytokines , chemokines and eicosanoids(71;351)  
Tumour necrosis factor alpha (TNF) and interleukin-1 (IL1), are two such 
cytokines which are produced by activated KC and most commonly implicated in 
hepatic IRI (72;188;369). Both these cytokines induce interleukin 8(IL8) synthesis   27
(383;384). IL8 is a CXC chemokine and a potent inducer of neutrophil chemotaxis 
and activation in vitro and in vivo(157;388). These cytokines and chemokines 
upregulate cellular adhesion molecules like 
1)  Selectins (P-selectin, E-selectin, L-selectin). 
2)  Integrins (MAC 1, LFA 1, VLA 4). 
3)  Immunoglobulins (ICAM-1, VCAM-1, PECAM-1). 
Thus initiating the adhesion molecule cascade leading to PMN recruitment into 
reperfused tissues by margination, rolling, firm adhesion, diapedesis and migration 
into the extravascular tissue (311;351;388). 
1.8 Role of adhesion molecules in liver ischaemia reperfusion injury 
Neutrophils are involved in both phases of liver IRI. Neutrophil recruitment is a 
multistep process which involves initial contact and adhesion with the endothelium, 
transendothelial migration and subsequent parenchymal cell adherence and 
damage(70). After IRI cellular adhesion molecules (CAM) are activated and/or 
upregulated on the surface of neutrophils and SEC(351). The inflammatory response 
is achieved via sequential steps which include the activation of leukocytes by 
cytokines(72;311;388), and increased adhesion molecules expression(71;403). The 
increased adhesion molecules expression results in rolling of the leukocytes on the 
sinusoidal lining cells(59;311), leukocyte adhesion to the sinusoidal cell lining via 
intercellular adhesion molecule-1 (ICAM-1)(311;403) , and leukocyte extravasation 
and tissue infiltration via the interaction of integrin matrix receptors and extracellular 
matrix molecules such as collagen and laminin (25;261).   28
Figure 1.1 Role of ICAM-1 in PMN capture and transendothelial migration 
 
In normal liver tissue, low constitutive expression of ICAM-1 can be found on the 
hepatic endothelium and on KC. Although ICAM-1 is not detectable in hepatocytes , 
it is upregulated by cytokines on virtually all liver cells(379). Intravital microscopic 
studies have demonstrated leukocyte adhesion to endothelial cells of both sinusoids 
and postsinusoidal venules after warm (292) and cold ischaemia and 
reperfusion(327). It has also been shown that leukocyte adhesion in postsinusoidal 
venules, but not in sinusoids, is mediated by ICAM-1 and that ICAM-1- mediated 
leukocyte adherence is responsible for the manifestation of excretory dysfunction 
and hepatocyte damage(403). 
Pre-treatment with monoclonal antibodies to ICAM-1, lymphocyte function 
associated antigen-1 and CD 18 before induction of rat lobar I/R resulted in a 
reduced leukocyte infiltration and lipid peroxide level and enhanced the recovery of 
hepatic ATP with increased survival rate(261).   29
1.9 Role of reactive oxygen species in liver ischaemia reperfusion injury  
Aerobic metabolism releases ROS which under normal circumstances are neutralized 
by diverse antioxidant mechanisms(389). Under stress the balance between  ROS and 
antioxidants shifts towards ROS leading to oxidative stress and 
cytotoxicity,(144;400).There is large body of evidence for the role of oxygen free 
radicals as a mediator of the microcirculatory and parenchymal cell injury associated 
with I/R injury(144). Activated KC have been identified as the major source of ROS 
formation in the early phase of IRI (33;184). Within the liver, the cytotoxic effects of 
ROS translate into nitrosylation of iron-sulfur groups and tyrosine residues, 
inactivation of the heme group and lipid peroxidation, (144;340). ROS can be 
potentially inhibited by antioxidant agents and therefore several studies have focused 
in modulating the severity of IR injury with various pharmacologic agents including 
allopurinol(231), N-acetylcysteine (134;145), α-tocopherol(260), enzymatic 
superoxide dismutase (SOD)(269) and catalase(144;269). 
Endogenous antioxidant levels decrease significantly during reperfusion, therefore 
the administration of exogenous antioxidants particularly in the early stages of 
reperfusion  could significantly decrease the severity of IR injury(206;260) . 
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Table 1.2: The role of reactive oxygen species in ischaemia reperfusion injury 
 
Lipid Peroxidation 
Activation of proteases 
↑ TNF-α, PAF & IL-1 
Activation of  NFκβ & AP-1 
↑Expression of adhesion molecules 
Microcirculatory failure 
Apoptosis 
 
Key: ↑= increased, TNF-α = tumour necrosis factor alpha, IL-1= interleukin 1 
PAF= platelet activating factor, NFκβ= nuclear factor Kappa beta, AP-1 = activator 
protein 1 
 
1.10 Role of nitric oxide and nitric oxide synthase in liver ischaemia reperfusion 
injury 
Nitric oxide (NO) a potent biologic mediator is the end product of the enzyme NOS 
(nitric oxide synthase)(377). Since the identification of NO as the endothelium 
derived relaxation factor in 1987 (297) a number of physiological actions have been 
attributed to it which include the following ; 
1)  Decreased inflammatory cell and platelet activity(63;321)  
2)  Decreased expression of cytokines and adhesion molecules(86;252) and 
3)  NO also acts as a free radical via its conversion to peroxynitrite (ONOO
)(307). 
NO is synthesized via oxidation of arginine by NOS and can be formed in liver by 
hepatocytes, KCs, and endothelial cells (377). There are two major isoforms of NOS 
in the liver ; a)endothelial NOS (eNOS) or constitutive NOS and b) inducible NOS 
(iNOS)(377). eNOS is expressed constitutively and it’s activity is dependent on Ca
 
and calmodulin(398), while iNOS is expressed by macrophages (including KCs) and   31
neutrophils in the liver. iNOS is upregulated by extracellular stimuli like cytokines 
and lipopolysacharides (LPS), leading to production of much higher levels of NO as 
compared to eNOS alone(377). These inflammatory mediators (i.e. cytokines and 
LPS), activate NF, which plays a pivotal role in expressional regulation of iNOS 
gene (173). iNOS activity is independent of intracellular calcium levels and produces 
NO at magnitudes several orders greater than eNOS (138;217). 
During Ischaemia intracellular levels of NADPH and oxygen fall leading to 
decreased levels of NO, since NADPH and oxygen are essential for NOS 
activity(365). Upon reperfusion excessive Ca
 entry into endothelial cells activates 
eNOS leading to a burst in NO production which is transient due to functional 
impairment of endothelial cells secondary to the hypoxic insult(240;307). Also in the 
immediate reperfusion period a large amount of arginase is released which results in 
depletion of L-arginine(346). iNOS induction requires several hours and iNOS 
activity is required for dose dependant production of NO which has been shown 
previously in animal models of hepatic IRI using different doses of L-arginine (290). 
This dose dependant production of NO was observed only after 6 hours (290). 
However, the role of NO produced during reperfusion is complex and controversial. 
Administration of both selective and nonselective inhibitors of NOS results in 
marked aggravation of post ischemic liver injury(77;222). While increasing NO 
availability by using  NO precursor (e.g. L-arginine) or NO donor (e.g. FK409) 
markedly decreases reperfusion injury (222;290;345). On the contrary  use of S-
nitroso N acetyl penicillamine to generate high concentration of NO in isolated 
perfused rat liver results in functional and morphological impairment of liver 
sinusoids (87). In hepatocyte cell cultures NO has been shown to stimulate   32
apoptosis(407), while in a IRI model using isolated perfused hepatocytes NO was 
shown to attenuate injury at low doses but aggravate it at high doses (115). 
Thus the effects of NO can be likened to a double-edged sword, wherein low 
concentrations of NO (generated by eNOS activation) are involved in the regulation 
of vascular tone and are beneficial to the outcome of IRI, while high levels of NO 
(generated by iNOS activation) are involved in inflammatory processes and are 
detrimental in IRI. 
1.11 Role of complement in liver ischaemia reperfusion injury 
The complement system is an integral part of the body’s humoral defence 
mechanism and also a primary mediator of inflammatory processes(10;128). The 
complement system consists of a number of proteins, which circulate in the plasma 
in an inactive form and are activated by proteolytic cleavage (10;128). The classical 
or the alternative pathway can activate this system. In hepatic IRI complement 
cascade is activated by both the classical and the alternative pathways by the 
pathophysiologic events of IRI (16). 
Complement activation results in three major effects:  
1)  Generation of opsonins (C3b,iC3b) which promotes binding and phagocytosis 
of microorganisms and particles by phagocytic cells via their complement 
receptors (10;128). 
2)  Generation of anaphylatoxins (C3a and C5a) which are proinflammatory 
mediators and activate endothelial cells, neutrophils, macrophages (KC), and 
mast cells(61;128;185;390). C3a and C5a also contribute to neutrophil 
chemotaxis, and increased vascular permeability within the liver (193;303). 
Activated endothelial cells lead to fibrin deposition, platelet aggregation and 
adhesion of neutrophils to the endothelium(61;193). These complement related   33
pathophysiologic events lead to failure of hepatic microcirculation which is an 
important determinant of postischemic liver function(270;385;402). 
3)  Formation of membrane attack complex (MAC) on cell surfaces (factors 5b-9) 
which  
a)  can directly induce target cell lysis (185;195). 
b)  activates endothelial nuclear factor kappa beta (NF) to increase 
leucocyte adhesion molecule transcription and expression (i.e. ICAM 1, 
VCAM 1, P selectin) (69). 
c)  promote leucocyte activation and chemotaxis by induction of IL8 and 
monocyte chemoattractant protein 1 (MCP1) (69). 
d)  MAC also alters vascular tone by inhibition of endothelium dependant 
relaxation and decreased endothelial cyclic GMP (69). 
Thus although complement activation occurs during the early phase of IRI, it also 
contributes to the later neutrophil mediated injury during the late phase of IRI. 
1.12 Role of molecular mechanisms in liver ischaemia reperfusion injury 
When the liver suffers an ischaemic insult, the alterations induced by the oxidative 
stress can exceed the compensatory capacity of the liver, resulting in cell death. The 
ischaemic event can reprogram gene expression of the surviving cells, initiating 
cellular mechanisms that allows them to regenerate  and remodel(65;114). One of the 
key transcription factors involved in mediating  liver regeneration following IRI is 
nuclear factor kappa B(NF-κB)(393;426). 
NF-κB is normally found in the cytoplasm attached to the inhibitory protein IκB, 
which is degraded during oxidative stress allowing the translocation of NF-κB to the 
nucleus(426). When activated NF-κB induces the synthesis of iNOS, cytokines 
(TNF-α), chemokines and adhesion molecules (ICAM-1) (140;426). The key   34
mechanism for NF-κB activation is by ROS production particularly H2O2(246). ROS 
production is a direct consequence of the IRI and via increased TNF-α production 
immediately following liver IRI(33;184;251). In normal hepatocyte, glutathione and 
other thiols dissipate excess ROS(117). ROS also activate of NF-κB, which acts as 
initiator of liver regeneration. Exhaustion of these intracellular defence mechanism 
results in excess ROS which then initiates mitochondrial dysfunction and activation 
of caspases leading to cell death(117). 
Antioxidant administration reduces NF-κB activation by: 
1)  Mopping up excess ROS  
2)   By acting as an anti-inflammatory agent during the late phase of IRI (370). 
Other genes that may participate in IRI include those of ET-1, NOS-3, heme-
oxygenase and those of the heat stress factor proteins and ROS have been 
documented to either activate or modulate all these cell pathways(3). 
1.13 Apoptosis and necrosis in liver ischaemia reperfusion injury 
During reperfusion, TNF-α, ROS, and other mediators activate many of the proteins 
involved in apoptosis such as caspase-3 and caspase-8 along with release of 
mitochondrial cytochrome C to the cytoplasm which initiates the cascade of events 
culminating in DNA destruction and cell death(340). However, it is still not clear 
whether apoptosis or massive necrosis is the final event, which predominates cell 
death following IRI. Lemasters et al(241) have proposed the theory of 
necroapoptosis suggesting that both cell death mechanisms occur simultaneously 
during ischaemia and overlap during reperfusion. The ischaemic stimulus can 
culminate in necrosis or  apoptosis , depending on the interaction of other factors like 
significant reductions in cellular ATP levels or the fat content of the liver(264;339) 
Hence, variety of mediators and signals are involved in the pathogenesis of hepatic 
IRI, which can compensate for the absence of one mediator. Therapeutic strategies to   35
ameliorate IRI in liver and improve outcomes have recently been summarized by 
Clavien and colleagues(66). 
The pathophysiologic processes involved in liver IRI is illustrated in figure 1.2. It 
would appear that ROS and KC activation are the two primary events in liver IRI and 
modulating these early events would ameliorate this injury.   36 
Figure 1.2: Pathophysiology of hepatic ischaemia reperfusion injury 
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Chapter 2 
Therapeutic modulation of liver ischaemia reperfusion injury 
with emphasis on antioxidants 
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IRI is a complex pathophysiological process involving multiple mediators which act 
in an autocrine and paracrine manner to augment the original injury. This cascade of 
proinflammatory events induces both acute functional and structural changes in the 
organ leading to organ dysfunction and failure(32;66). Thus attenuation of IRI by 
strategies targeting various mediators and cell populations at different levels of the 
cascade may be helpful in improving both short and long term organ function. 
2.1: Cytokine modulation to reduce liver ischaemia reperfusion injury 
Hepatic IRI is inevitable in surgical procedures for liver trauma and hepatectomy as 
well as liver transplantation. Cytokines are pivotal factors in neutrophil-mediated 
liver injury following liver IRI, while various other mediators are involved in this 
insult. Inflammatory cytokines such as TNF-α are associated with the induction of 
cellular adhesion molecules and hepatic microcirculatory impairment based on 
neutrophil-vascular endothelial cell interaction(71). Members of the chemokine 
family such as IL-8, CINC, MIP-2, and MCP-1 are involved in neutrophil infiltration 
in the liver and remote organs(314).The roles of various cytokines involved in liver 
IRI is summarized in table 2.1. Lentsch et al  have recently reviewed the role of 
cytokines in hepatic IRI(178). 
2.1.1: TNF-α  
TNF-α is a powerful proinflammatory mediator which plays a central role in 
initiation and perpetuation of the inflammatory cascade following liver IRI(247). It 
also stimulates signal transduction pathways leading to increased gene expression for 
secondary inflammatory mediators(247). TNF-α is mainly produced by activated 
KCs during early reperfusion and blockade of this mediator has been shown to 
ameliorate liver IRI, not only by reducing the production of secondary mediators but   39
also, by preventing the expression of VCAM and expression of CXC chemokines 
which are chemotactic for neutrophils(70;72;351). 
2.1.2Chemokines (IL-8 & MCP-1): 
Chemokines (IL-8 & MCP-1) are small peptide mediators whose names are derived 
from their function of promoting directed chemotaxis in nearby responsive cells. 
There are currently 4 branches of the chemokine family which include 
CXC,CC,CX3C and C(351). Due to the extensive functional overlap between the 
various chemokines blockade of any one of these mediators does not completely 
ameliorate IRI. However, studies have shown that chemokine blockade leads to 
reduced neutrophil accumulation and subsequent cellular injury(243). The receptors 
for these mediators are expressed on neutrophils and they mediate the chemotactic 
response of these cells towards their ligands. These present a more attractive target 
since only two of these receptors are expressed on neutrophils(71). 
2.1.3: Adhesion molecules  
Adhesion to vascular endothelium occurs early during reperfusion and is responsible 
for activation and sequestration of neutrophils. This is mediated by adhesion 
molecules which are expressed on both neutrophils and endothelial cells(389). The 
three main classes of adhesion molecules are selectins, integrins, and 
immunoglobulin like adhesion molecules. Selectins are expressed on both 
neutrophils and EC and they capture circulating leucocytes to bring them into close 
proximity to the endothelial cells. There are 3 members of this family i) E-selectin 
which are expressed on EC, ii) L-selectins which are expressed on leucocytes and  
iii) P-selectin which are expressed on platelets and EC. Multiple studies have utilised 
small molecule inhibitors of selectin function to target these interactions and have 
attenuated neutrophils accumulation and liver injury(59). Integrins are expressed on 
leucocytes and they bind to the immunoglobulin like adhesion molecules which are   40
expressed on EC. The binding of these two adhesion molecules promotes 
transendothelial migration of leucocytes into the tissue(68). In the liver two 
immunoglobulin family members i.e. intercellular adhesion molecule (ICAM-1) and 
vascular cell adhesion molecule-1 (VCAM-1) control the majority of neutrophils 
adhesion and transmigration blockade of which dramatically reduces neutrophil 
accumulation and injury(116;232;389). 
Table 2.1: Summary of the role of cytokines in ischaemia-reperfusion injury 
 
Cytokine Function related to ischaemia reperfusion injury 
TNF-α 
Acts on endothelial cells to increase surface adhesion molecules, 
activates the coagulation cascade and Kupffer cells,  
activates leucocytes infiltrating the ischaemic area 
IL-1 
Mediates local inflammatory response by activation of leucocytes, 
induces synthesis of acute phase reactants, acts on endothelial cells 
to increase surface adhesion molecules 
IL-8  Promotes invasion of leucocytes into ischaemic areas,  
acts as activator of neutrophils  
IL-6  Stimulates production of IL-1 and TNF-α  antagonists,  
induces liver synthesis of acute phase proteins like fibrinogen 
PAF 
Mediates vasoconstriction, induces platelet aggregation, promotes 
neutrophil adherence to endothelium, stimulates production of 
ROS, leads to aggregation and degranulation of neutrophils 
TGF-β  Proapoptotic properties and involvement in SEC apoptosis 
 
Key: TNF-α = Tumour necrosis factor alpha, IL-1 = interleukin 1, IL-6 interleukin 6, 
IL-8= interleukin 8, PAF = platelet activating factor, TGF-β = tumour growth factor 
beta 
2.2: Prostaglandin therapy in modulating liver ischaemia reperfusion injury 
Prostaglandins (PGs) are biologically active polyunsaturated fatty acids derived 
primarily from arachidonic acid, via the cyclooxygenase (COX) or lipooxygenase 
pathways to form either prostaglandins and thromboxane or leukotrienes(310). The 
cyclooxygenase pathway produces PGs (D, E and F), thromboxane and prostacyclin.   41
The lipooxygenase pathway is active in leucocytes and macrophages synthesizing 
leukotrienes. They are short lived hormone like chemicals which regulate cellular 
activities on a moment to moment basis and liver is the major organ involved in 
synthesis, degradation and elimination of these by-products of the arachidonic acid 
pathway (300). 
During the last decade, substantial evidence has accumulated on the cytoprotective 
effects of PGs on liver IRI , which has been extensively documented in various 
reviews (174;300;310). 
PGs have been shown to protect against liver IRI by 
1)  Increasing liver perfusion and inhibiting leucocyte & platelet aggregation by 
downregulating intercellular adhesion molecules (300) 
2)  Protecting SECs from apoptosis (430) 
3)  Suppressing thromboxane A2 and increasing PGI2 production (156) 
4)  Inhibiting Ca
+2 –calpain –mu- mediated IR injury (216) 
5)  Ameliorating protease release and ODFR generation from activated leucocytes 
with PGI2 (310) 
6)  KC activation leads to synthesis of TNF-α which induces PGE2 production, 
which subsequently inhibits TNF-α synthesis (229) 
7)  Intra-arterial infusion of PGE1 has been shown to protect against liver IRI both 
experimentally and clinically to prevent hepatic failure following orthotopic 
liver transplantation (OLT) (9;175) 
8)  PGI2 has been shown to reduce IRI following OLT  by improving hepatic 
splanchnic oxygenation (281) 
9)  Treatment of donor liver with PGI2 increased graft viability in living related 
liver transplantation both experimentally and clinically (227;342)   42
10)  PGs also augment liver regeneration directly by protecting hepatocytes and 
indirectly by expressing critical factors needed for cell proliferation(26;41;181) 
Although PGs have been shown to have multiple beneficial effects in both 
experimental and clinical scenarios, there are still questions remaining regarding its 
optimal dose, administration routes and, timing and because of its very short half life 
and metabolisation by the lungs. The other important factor being the action of PGs 
is downstream following the initial injury hence on it’s own they would not 
completely ameliorate IRI. 
2.3: Gene therapy in modulating liver ischaemia reperfusion injury 
The cellular mechanisms of liver IRI are complex and multimodal and exploring 
genes to target specific events in this complex pathway may be a viable therapeutic 
strategy. Recent experimental studies using gene transfer methods have provided 
encouraging results in ameliorating liver IRI. Studies using gene therapy targeting 
specific genes in liver IRI are summarised in table 2.2. 
2.3.1: Antiapoptotic Genes (BCl-2/BCL-XL and BAG-1) 
 The proto-oncogene Bcl-2 and Bcl-2 related gene Bcl-xL which act by blocking 
apoptosis and necrosis are potent regulators of programmed cell death and a key 
target for therapeutic manipulation (228). Overexpression of Ad-mediated Bcl-2 
gene significantly reduces hepatocytes apoptosis, improves hepatic function and 
prolongs survival(29). Similar results have been reported by Swaitzki et al who 
demonstrated the cytoprotective effect of Ad-mediated Bag-1 gene transfer in rat 
liver IRI(322). 
2.3.2: Antioxidant Genes: SOD and HO-1, Ferritin 
 Early activation of NFκB and AP1, following liver IR leads to early transcriptional 
activation of genes which encode inflammatory cytokines and acute cellular 
responses further augmenting the extent of hepatic IRI(443). Gene transfer of  Ad-  43
Cu/Zn-SOD (cytosolic superoxide dismutase) and Ad-MnSOD (mitochondrial 
superoxide dismutase) reduced serum transaminases and preserved histological 
features suggesting that reduced cytokine and chemokine production is dependent on 
redox-sensitive transcription factor NFκB(419;443). Heme oxygenase 1 (HO-1)is a 
stress responsive protein which has been shown to exhibit cytoprotective effects after 
liver IRI. Upregulation of HO-1 gene overexpression correlated with preserved 
hepatic architecture, improved LFT’s, reduced T cell and macrophage infiltration and 
increased graft survival(6;208;394). Similarly ferritin induction due to action of  
HO-1 on the heme porphyrin ring causes release of Fe
+2 which plays a role in 
formation of OH
- and OH through the Fenton reaction. Ad vector carrying the ferritin 
heavy chain (H-Ferritin) gene has been shown to protect rat livers from IRI by 
inhibition of endothelial cell and hepatocyte apoptosis(27). 
2.3.3: Immunoregulatory cytokines: IL-10 and IL-13 
Studies have shown correlation of overexpression of IL-13 which regulates the liver 
IRI inflammatory response via the signal transducer and activator of transcription 6 
(STAT 6) pathway while IL-10 induces HO-1 gene expression(113;207). Ad-IL-13 
gene transfer has shown cytoprotective effects in both warm and cold Ischaemia 
models, with improved hepatic function, reduced neutrophil aggregation, and 
prevention of hepatic apoptosis 
2.3.4: IL-1 Receptor antagonist: 
 IL-1 is a proinflammatory cytokine which plays a central role in liver IRI (351). 
Gene transfer of Ad-mediated IL-1 receptor antagonist improved hepatic function 
and animal survival following partial hepatic IRI with amelioration of TNF-α, IL-1 
and IL-6 (158).   44
2.3.5: Transcription factor: NF-κB 
Activation of NF-κB by ROS following IRI leads to overexpression of 
proinflammatory cytokines further augmenting the IR injury. Thus inhibition of  
NF-κB activation by redox gene therapy have shown beneficial effects against 
apoptosis and protection against proinflammatory cytokines (443). 
2.3.6: T-cell costimulation blockade: CD40-CD154 
CD4+ T lymphocytes mediate key cellular events in liver IRI and the CD40-CD154 
costimulation provides the essential second signal in the initiation and maintenance 
of T cell dependent immune responses (209). Blockade of the CD40-CD154 
interaction by pre-treatment of liver isografts with Ad-CD401 gene significantly 
attenuated the inflammatory response following liver IRI with prevention of 
apoptosis and preservation of liver architecture (209). 
2.3.7: RNA interference 
RNA interference involves injection of small interfering RNA duplexes to 
downregulate gene expression like the genes involved in hepatic IRI providing a 
promising therapeutic modality (359). 
Thus targeting specific genes to protect against IRI is promising; however current 
laboratory protocols need to be modified prior to application in the clinical setting 
which might be possible with further advances in gene therapy technology. 
2.4: Role of antiapoptotic molecules in liver ischaemia reperfusion injury 
Liver IRI triggers a cascade of cellular events leading to programmed cell death, thus 
inhibition of these proapoptotic pathways may provide a viable therapeutic 
alternative. Apoptosis can occur via a) extrinsic pathway or death receptor signalling 
and b) the mitochondrial pathway or the intrinsic pathway(151;433). Death receptor 
mediated apoptosis is in turn mediated by Type 1 and type 2 cells. Apoptosis   45
induction in Type 1 cells leads to activation of large amounts of caspase 8 (initiator 
caspase) which directly activates caspase 3 (main executioner caspase), while type 2 
cells initially activate only very small amounts of caspase-8(433). 
At the cellular level death receptors (Fas, TNF-receptor 1, and TNF related apoptosis 
inducing ligand; TRAIL receptors 1&2), which belong to the TNF superfamily and 
induce apoptosis directly are the first potential targets for antiapoptotic strategies 
against liver IRI.(433). There are few studies which have studied impact of Fas 
signalling in hepatic IRI and inhibition of Fas signalling has not been of conclusive 
benefit in warm hepatic IRI(319). Contribution of TNF-R1 signalling in the cold 
hepatic IRI is not established, while in warm liver IRI lack of TNF-R1 has been 
shown to improve survival, reduce apoptosis and decrease liver injury(319). The 
impact of TRAIL induced apoptosis in liver IRI has not been investigated. 
The major form of apoptosis seen in vertebrate cells proceeds via the intrinsic or the 
mitochondrial pathway which is initiated by various second messengers like ROS, 
Ca
+2, stress kinases, ceramides and proapoptotic Bcl-2 members leading to 
permeabilization of mitochondrial membranes and release of nuclease and protease 
activators(435). Thus strategies to prevent cell death in liver IRI might include 
inhibition of mitochondrial membrane permeabilization or events downstream of 
mitochondria. Modulation of expression of Bcl-2 proteins as a strategy to protect 
against hepatic IRI has been shown to be effective in several studies involving warm 
liver IRI (29;302;338) , while similar studies in context of cold preservation injury, 
investigating the direct impact of Bcl-2 family are still missing. However 
overexpression of Bag-1 which can stabilise Bcl-2 has been shown to reduce liver 
injury and improve survival (322). 
Inhibition of mitochondrial membrane permeabilization by a number of agents have 
been shown to reduce caspase 3 activation and ameliorate liver injury (171;213;271).   46
Similarly inhibition of caspases by pharmacological means has been shown to be 
effective in preventing both cold and warm liver IRI(139). However, caspase 
inhibition alone does not completely protect against liver IRI since direct cell lysis is 
independent of intracellular mediators and also due to presence of mediators which 
can lead to apoptosis independent of caspases (139). Calpains are cytosolic cysteine 
proteases which require Ca
+2 for their activity have been investigated in cold and 
warm liver IR. Inhibition of calpains significantly protected livers from cold and 
rewarming IRI (223;352). Cathepsins B and D are lysosomal proteases which are 
released by stimulation of TNF-R1 and activation of caspase -8 and which in turn 
activate a lysosomal pathway of apoptosis (153). Increased release of Cathepsin B 
and D following reperfusion after 24 hours of cold storage was associated with 
reduction in lysosomal integrity in fatty but not lean livers and increased markers of 
apoptosis (18). Genetic inactivation of cathepsin B or application of specific inhibitor 
ameliorated signs of hepatocellular apoptosis and necrosis (18). 
Recent experimental evidence has shown reversible blockade of p53 dependent 
transcriptional activation and apoptosis, by Pifithrin-α, a specific p53 inhibitor in a 
isolated perfused rat liver after 24-48 hours of cold storage with significant reduction 
of apoptosis and SEC detachment (103).Mitogen activated protein kinases (MAPKs) 
are a family of proteins involved in regulating cellular activities from gene expression 
to programmed cell death. Application of stress kinase inhibitor SB202190 abolished 
JNK (a MAPK) activation and completely inhibited caspase 3 activation (78). Similar 
results have been reported with use of diltiazem and FK-506 (79;80) however, due to 
the additional properties of these drugs these experiments do not confirm the role of 
JNK activation in hepatic IRI. 
Thus even though a number of substances inhibiting pathways of programmed cell 
death have been investigated and found to be beneficial in both warm and cold liver   47
IRI. However, none of these substances have been used clinically. This might be 
because these substances act downstream from the initial stimulus which initiates IRI 
and also other strategies like IPC and RIPC are more easily applicable particularly in 
the setting of liver resectional surgery.   48 
Table 2.2: Summary of gene therapy using specific target genes in hepatic ischaemia reperfusion injury 
Target Gene  Vector  Treatment  Animal  Authors 
Anti-oxidant SOD  Adenovirus  Donor  Mice  Zwacka et al;1998 
Anti-oxidant SOD  Adenovirus Donor  Rats  Wheeler et al; 2001 
Anti-oxidant HO-1  Adenovirus Donor  Rats  Amersi et al 1999 
Anti-oxidant HO-1  Adenovirus Donor  Rats  Coito et al;2002 
Anti-apoptotic Bcl-2  Adenovirus Donor  Rats  Bilbao et al, 1999; 
Anti-apoptotic Bag-1  Adenovirus Donor  Rats  Sawitzki et al 2002 
Cytokines, IL-13  Adenovirus Donor  Rats/Mice  Ke B et al 2003,2004 
Cytokine antagonists, IL-1R antagonist Adenovirus/Cationic  liposomes   Donor Rats  Harada et al 2002 
Protective, ferritin  Adenovirus Donor  Rats  Berberat et al,2003 
Costimulatory blockade, CD40Ig  Adenovirus Donor  Rats  Ke B et al ;2004 
Transcription factor, NFκB  Adenovirus Donor  Rats  Takahashi et al ;2001 
TLR-4 & HO-1 signalling  Adenovirus  Donor  Wild type knockout mice  Ke B et al; 2007 
 
Key: SOD = Superoxide dismutase, HO-1 = hemeoxygenase 1, Bcl-2 = B cell lymphoma 2, Bag-1= Bcl-2 associated anthogene, IL-13 = interleukin 13,  
IL-1R = interleukin 1 receptor, NFκB = nuclear factor kappa beta, TLR-4 = toll like receptor 4, CD40 Ig = CD40 immunoglobulin,     49
2.5: Surgical strategies to modulate liver ischaemia reperfusion injury 
Surgical resection of liver tumours with disease restricted to the liver or in selected 
cases with limited extrahepatic disease offers a curative option with improved 
survival in conjunction with chemotherapy(66).Pringle’s maneouver and total 
vascular exclusion are used to minimize blood loss and need for transfusion 
intraoperatively(226;305). Both techniques, however result in inevitable ischaemic 
injury to the liver which may subsequently impair regeneration after major 
hepatectomy(22;23). I/R injury also occurs due to intraoperative mobilisation and 
compression of the liver due to retraction(327;331). Liver transplantation either from 
a deceased/living donor is the standard of care for selected patients with end stage 
liver dysfunction. However, the inherent IRI during organ harvest, storage and 
reimplantation is a significant cause of morbidity and mortality in these patients 
(65;66;331). 
3 surgical strategies have been proposed to attempt to reduce liver IRI. 
2.5.1: Ischaemic Preconditioning  
This consists of one or more brief episodes of Ischaemia followed by a short interval 
of reperfusion, before a prolonged period of ischaemia. Number of extracellular 
mediators like adenosine, nitric oxide (NO), bradykinin and intracellular messengers 
such as p38 MAPK, Ik Kinase; signal transducer and activator of transcription-
3(STAT-3) and transcription factors including NFκB and heat shock transcription 
factor 1 have all been implied in the protective mechanisms for this 
strategy(52;340).The benefits of  ischaemic preconditioning (IP) on energy 
metabolism, inflammatory mediators including ROS and TNF-α, mitochondrial 
dysfunction , KC activation and microcirculatory dysfunction associated with liver 
IRI have been described(17;142;212;344). IP has been successfully applied in human   50
liver resection and transplantation(12;17;58;67;199;224;288). These studies 
demonstrate that IP decreases the extent of IRI in both major liver resection and 
transplantation, however clinically significant benefit has yet to be demonstrated from 
the use of donor IP in clinical liver transplantation. This may be due to multiple 
uncontrolled variables during donor organ procurement, preservation, recipient 
factors, as well as implantation process and postoperative management. Also these 
studies lack sufficient power to demonstrate survival advantages due to intergroup 
variations and technical factors like the time used. IP which is derived from animal 
studies may not be long enough to confer significant protection and improve survival. 
The use of IP in solid organ transplantation and indeed in major liver surgery has 
other limitations including the potential for vascular injury and worsening post 
transplant function. The other major limitation is inability to apply this technique to 
non heart beating organ donors, where the patient sustains cardiopulmonary arrest 
before organ procurement.  
2.5.2: Postconditioning   
Post conditioning (PC) is defined as repetitive brief cycles of reperfusion performed 
at the onset of reperfusion(439). The timing of postconditioning is critical ( at the 
initiation of reperfusion) to attain optimal protection from IRI(215). The protective 
effect has been proposed to be via recruitment of survival kinases which are also 
known as reperfusion injury salvage kinases or RISK pathway(164;442). The use of 
PC has not yet made its way into the transplant setting but it outlines an interesting 
strategy which may be more beneficial to the transplanted organ than IP because of 
the oxidative burst at onset of reperfusion. Also this strategy may be useful to all 
transplants, irrespective of the organ procurement technique since it is applied just 
prior to reperfusion during implantation.   51
2.5.3: Remote ischaemic preconditioning 
RIPC is a novel method of protecting the target tissue and may be defined as the 
induction of nonlethal stress by brief ischaemia to an organ distant from the organ 
undergoing IRI resulting in systemic and local tolerance to subsequent IRI(205;374) 
RIPC stimulus induces release of biochemical messengers which act either by 
bloodstream or via neurogenic pathways resulting in reduced oxidative stress and 
preservation of mitochondrial function. Numerous mechanisms including endothelial 
NO, ROS, Kinases, catecholamines and ATP channels have been proposed(205). 
Originally described in the canine heart, it’s protective effect was subsequently 
confirmed in various organ systems(204-206;373). The main advantage of this 
strategy is that it can be readily applied during organ procurement and implantation 
with minimal or no adverse effects on the target organ. Further clinical trials are 
awaited to assess the effectiveness of this strategy. 
2.6: Role of reactive oxygen species and antioxidant therapy in liver ischaemia 
reperfusion injury 
A radical is any atom or bio molecule which contains unpaired electrons making it 
more reactive than the corresponding non radical(144). Oxygen is the main source of 
free radical formation due to its high bioavailability and the most biologically 
relevant radicals are the Superoxide anion (O2
.-), the hydroxyl radical (OH
-) and 
nitric oxide (NO). Some other species are intermediate in the metabolism of O2 and 
NO but are not radicals since they do not contain unpaired electrons(146). These 
intermediate species along with the radical species are called ROS (H2O2 and 
hypochlorous acid) and RNS (peroxynitrite ONOO
-)(144). Liver IRI is at least 
partially induced by ROS and RNS with concomitant consumption of endogenous 
antioxidants, formation of mitochondrial permeability transition pores and apoptotic 
or necrotic cell death (143;146).    52
The role of ROS in liver IRI is summarised in table 2.3 
 
Table 2.3: Role of reactive oxygen species (ROS) in liver ischaemia reperfusion 
injury 
 
Function References 
 
Enhance pro-inflammatory gene expression (TNF-a, IL-1, IL-8, cellular 
adhesion molecules) 
(243;253) 
 
Induce expression of the transcription factors NF-kB and activator 
protein-1  
(443;159) 
Direct cellular damage through protein oxidation and degradation, lipid 
peroxidation and DNA damage
(189) 
Direct induction and regulation of apoptotic and necrotic cell death 
 
(312;319) 
Inactivation of antiproteases  (189;414) 
Induction of protective stress genes in hepatocytes  (19) 
Formation of mediators involved in regulating sinusoidal blood flow & 
liver regeneration 
(279;299) 
 
 
Key: TNF-α, tumour necrosis factor-α; IL-1, interleukin-1; IL-8, interleukin-8; NF-kB, nuclear factor-
kappa B. 
 
The human body has endogenous antioxidant defence mechanism to protect it from 
damage by these free radicals whose primary function is to prevent initiation of 
oxidative damage or limit its propagation. However, oxidative stress results when 
these endogenous antioxidant systems are overwhelmed by excessive production of 
ROS and RNS(144). Hepatocytes are resistant to injury by ROS and RNS since they 
contain high intracellular concentration of glutathione (GSH), Superoxide 
dismutase(SOD), catalase and lipid soluble antioxidants(144).  
Antioxidants are a heterogeneous family of molecules which can be classified on the 
basis of their site of action viz. 
1)  Intracellular antioxidants: SOD, catalase, glutathione peroxidase and reductase 
enzymes, the tri-peptide glutathione, the polypeptide thioredoxine, the enzyme 
hemeoxygenase (HO) and peroxidases of the peroxiredoxin family.   53
2)  Extracellular antioxidants: which includes the metal binding proteins 
(Transferrin, lactoferrin, ceruloplasmin, albumin, haemoglobin and 
myoglobin), various low molecular weight substances (bilirubin, melatonin, 
Lipoic acid, coenzyme Q, uric acid and melamins),   
3)  Exogenous antioxidants: dietary constituents (ascorbic acid, α-tocopherol and 
carotenoids) and plant phenols (tocopherols, tocotrienols, flavonoids, 
anthocyanidins and phenylpropanoids) 
A large number of antioxidants have been shown to be beneficial in treatment of 
liver IRI and have been summarised in Table 2.4. As far as extracellular antioxidants 
are concerned there is a lot of experimental evidence to suggest their protective 
effects in hepatic IRI however, the majority have not yet been used in large or small 
clinical trials. Further information can be obtained from exhaustive existing reviews 
in the literature(56;124;144;259;264;437).   54
Table 2.4 List of antioxidant agents with beneficial effects in liver IRI 
Antioxidant Category  Species  Injury 
Type 
Mode of 
Adm. 
Dose Main  protective 
effect 
Authors (first) 
 
A-Tocopherol Vitamin-diet  Rat  WI  IM  30  and  300  mg/kg   Survival, Histology  Giacoustidis, 2002 
Α-Tocopherol Vitamin-diet  Rat  CI/WI  iv  50 IU/Kg  Histology  Gondolesi, 2002 
Α-Tocopherol / 
Ascorbate 
Vitamins-diet  Clinical   WI  iv  2 mg /  
1000 mg 
Better PT 
↓postop.complications
Cerwenka, 1999 
Ascorbate  Vitamin-diet  Rat  WI  iv  30 and 100 mg/kg  ↓ lipid peroxidation  Seo, 2002 
Coenzyme Q / 
Pentoxyfylline 
In vivo LMM agent  Rat  WI  IM/IP  10 mg/kg  / 
50 mg/kg 
↓ lipid peroxidation 
↑ GSH levels 
Portakal, 1999 
Idebenone  Coenzyme Q derivative  Pig  CI        Schutz, 1997 
Lipoic acid  In vivo LMM agent  Rat  CI  iv  500 μM Histology  Muller,  2003 
Deferrioxamine  Iron chelator  Dog  CI/WI  iv  20 mg / kg  ↓ AST activity  Park, 2003 
Trimetazidine Metal  chelator  Rat  WI  iv  /IP  2.5 mg / kg  Histology  Tsimoyiannis, 
1993 
Quercetin  Plant phenol  Rat  WI  po  0.13 mmol / kg  ↓ ALT, AST  Su, 2003 
Cyanidin  Plant phenol  Rat  WI  po  0.9 mmol / kg  ↓ lipid peroxidation  Tsuda, 2002 
Green Tea Extracts  Plant extracts 
(Catechines) 
Rat  WI  po  0.1 %  Histology  Zhong, 2002 
Magnifera indica  Plant extracts 
 
Rat  WI  po  250 mg / kg  ↓ AST, ALT 
↓ lipid peroxidation 
Sanchez, 2003 
Glutathione 
(GSH)  
In vivo LMM agent  Rat  WI  iv   100 μM/h/kg  ↓ ALT 
↑ survival 
Schauer-a, 2004
  
Glutathione   In vivo LMM agent  Rat  CI/WI  iv   100 μM/h/kg  ↓ ALT, ↑ bile flow  Schauer-b, 2004 
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N-acetylcysteine Thiol  compound 
GSH precursor 
Rabbit  WI  iv  150 mg / kg  ↓ ALT 
↑ microcirculation 
Glantzounis, 2004 
N-acetylcysteine/ 
Melatonin 
Thiol compound   Rat  WI  IP  150 mg/kg / 
10 mg / kg 
↓ AST, ALT 
↓ lipid peroxidation 
Sener, 2003
  
N-acetylcysteine  Thiol compound  Clinical  CI/ WI  iv  150 mg / kg  ↓ ICAM, ↓ α-GST Weigand,  2001 
Bucillamine  Thiol compound  Rat  CI/ WI  ipr 
iv 
15 mg / kg 
10 mg /kg 
Survival Amersi,  2002 
SOD derivatives  Intracellular enzyme  Rat  WI  iv  5000 IU / Kg  ↓ lipid peroxidation  Nguyen, 1999 
CAT derivatives  Intracellular enzyme  Rat  WI  iv  0.1 mg / kg  ↓ ALT, AST  Yabe, 1999 
Allopurinol  XO  Inhibitor  Rat  WI  IP  50 mg / kg  ↓ AST  Jeon, 2001 
Aminoguanidine  iNOS inhibitor  Pig  CI /WI  iv  10 mg / kg  Survival, histology  Kimura,  2003 
 
Key: Admin, administration; WI, warm ischaemia; im, intramuscular; CI, cold ischaemia; iv, intravenous; PT, prothrombin time;  LMM, low molecular molecule; deriv, 
derivatives; In, Intragastric; ip, intraperitoneal; AST, aspartate transaminase ; ALT, alanine transaminase;  ICAM-1, intercellular adhesion molecule-1; α-GST:α-glutathione 
S-transferase; ipr, intraportally;  XO, xanthine oxidase   56
Intracellular antioxidant in particular sulphydryl group containing compounds like 
thiols are central to the cellular antioxidant defence in mammals. These compounds 
exert their protective effect by reacting with ROS and RNS and thus scavenging the 
free radicals generated under conditions of oxidative stress(144). The main 
representative of this group is  glutathione (GSH) which serves as a substrate for 
glutathione peroxidase and directly scavenges ROS(144). Experimental evidence 
suggests that exogenous GSH administration ameliorates liver IRI, however in the 
clinical setting due to it’s large molecular size it is not efficiently transported into 
cells and thus may not be very effective particularly in situations associated with 
intracellular oxidative stress(146). The other limiting factor in GSH synthesis is 
requirement of intracellular cysteine which is extremely unstable in its reduced 
form. Other intracellular antioxidants like Superoxide Dismutase (SOD) and catalase 
have  shown ambivalent results in the literature largely due to short half life and lack 
of uptake of the intact protein into cells, to bypass these difficulties newer 
derivatives of SOD and catalase  have been developed by conjugation with 
carbohydrates, which facilitates their uptake into liver non parenchymal cells with 
promising results(144). Allopurinol a xanthine oxidase inhibitor, in low doses has 
not shown any protective effects against liver IRI but high doses when administered 
intraperitoneally have shown to be beneficial in liver IRI(200). 
 Hence, considerable research has focused on N-acetylcysteine (NAC), a) which is 
the redox state of cysteine, b) has a small molecular size and c) is rapidly hydrolyzed 
to cysteine intracellularly to provide the substrate for GSH synthesis and hence 
replenishing the intracellular GSH stores under conditions of extreme oxidative 
stress(144;146). 
NAC is a well documented substance in medicine. Its defined volume of distribution 
is 0.33 L/kg, its renal clearance is 0.21 L/hr/kg, and its elimination half-life is 2.27   57
hours(30). Originally, NAC has been used to liquefy mucus in bronchi; NAC is also 
the antidote for paracetamol poisoning(166). It should also be mentioned that 
cysteine derivatives have been intensively investigated in military medicine because 
of their protective effects against radiation and that NAC has been investigated as a 
modulator of radiographic contrast agent-induced nephrotoxicity(40). The role of 
NAC in Ischaemia-reperfusion injury is shown in Table 2.5 (357).  
Table 2.5: Postulated roles for NAC in Ischaemia reperfusion injury 
Against ROS: 
 Redox  mechanism  cysteine-cystine 
  Maintained tissue glutathione levels 
         ↑ glutathione reductase activity 
At cellular level 
Indirect protection against ROS by formation of mixed disulfides with SH 
groups of membrane peptide/enzymes 
Effect on platelet function 
  Action under low pH (ischaemic) conditions 
         Inhibit expression of iNOS mRNA 
        Block upregulated NF-κβ activity 
At microcirculatory level 
 Interaction  with  neutrophils 
  NAC induced ACE inhibition 
 Modulation  of  coagulation 
  Effect on adhesion processes (via adhesion molecules)  
 
Key: ROS = reactive oxygen species, SH= sulphydryl, NAC = N-acetylscysteine, ACE = acetyl 
coenzyme, 
The diversity in the pharmacological uses of NAC is due to the multiple chemical 
properties of the cysteine thiol of the molecule. These include its nucleophilicity and 
redox reactions. The main mechanism of action of NAC is through the metabolism to 
cysteine in vivo and synthesis of GSH(422). However, some effects of NAC are not   58
mediated by an increase of GSH, as suggested by experiments with inhibitors of 
GSH synthesis or the D-stereoisomer of NAC (D-NAC) that cannot be converted to 
GSH. These effects include direct scavenging of ROS and RNS, inhibition of 
apoptosis(429), antiproliferative effects(214) and direct reduction of functional 
protein thiols at the cell surface(235). 
Figure 2.1: Chemical structure of N-acetylcysteine 
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 2.7: Role of N-acetylcysteine in liver ischaemia reperfusion injury 
NAC has been recognized to protect the liver from warm and cold I/R injury 
(98;401) where it was used as a glutathione donor as it increased reduced glutathione 
levels in the liver after reperfusion (132;276). It was also seen to enhance sinusoidal 
perfusion by intravital microscopy on reperfusion and transplantation(220;221), and 
reducing neutrophil sequestration(381). Its use during preservation revealed reduced 
sinusoidal oxidative stress, and, under a glutathione-depleted conditions, reduced 
hepatocellular and sinusoidal oxidative stress(277).  The use of NAC-pretreatment in   59
a large animal transplantation model showed that NAC pre-treatment was associated 
with less cytolysis, transaminase elevation, better coagulation, reduced the incidence 
of graft dysfunction and primary non-function(313) although this is still controversial 
(257). NAC was also observed to reduce remote lung injury following liver I/R 
(412;413). Further investigation of the mechanisms by which NAC was able to 
produce these effects revealed that it inhibited TNF- and IL-10 (239), maintained 
tissue glutathione levels, reduced the rise in malondialdehyde, glutathione peroxidase 
and superoxide catalase, following I/R, and increased glutathione reductase activities 
(341). The effect of oxidative stress on NF- and iNOS was elucidated when NAC 
was seen to inhibit the expression of iNOS mRNA and block upregulated NF- 
binding activity on reperfusion (177). NAC was seen to inhibit the kinase 
JNK1/SAPK1, a member of MAPK family, which regulates cell adaptation to 
stressful conditions(78). The clinical benefit of NAC in liver I/R is 
ambivalent(60;221). This probably relates to differences in the method of NAC 
administration and the duration of follow up.  
2.8: Role of N-acetylcysteine in clinical liver transplantation 
The various clinical trials using NAC in liver transplantation are summarised in 
Table 2.6. In the first reported trial in clinical liver transplantation, NAC failed to 
show any beneficial effect of the intraoperative administration of NAC on 
hemodynamics and graft function in liver transplantation in cirrhotic patients (363). 
However it was later reported to produce a distinct reduction in I/R injury and 
improved liver function with less elevated peak transaminases, better 
microcirculation, improved liver synthetic function and a lower incidence of PNF 
(382). NAC was also observed to increase selectin shedding following OLT (376). 
Furthermore, it was observed to inhibited the increase in circulating ICAM-1 and   60
VCAM-1 24 hr after reperfusion in OLT and reduced the rise in alpha-glutathione S-
transferase after reperfusion of the donor liver (408). Although not all the effects of 
NAC observed in OLT were beneficial (375). Taut et al observed increased hepatic 
glutamine and urea production in patients treated with NAC. This would increase the 
oxygen and energy demand from a recently implanted graft resulting in metabolic 
disturbances (375). 
In the field of liver transplantation, there are six published small (9-30 patients in 
each group) clinical trials (5 randomised controlled trials and one open label pilot 
study) that assessed the effect of intravenous NAC administration and patient 
outcome. In the first study NAC improved oxygen delivery and consumption but had 
no effect in postoperative graft function, morbidity or mortality(38). The second 
failed to show any clear protection on postoperative graft function(363). The third 
clinical study showed that NAC administration was associated with better liver 
function, less hepatocellular injury and lower incidence of primary graft 
dysfunction(382). The fourth study showed that NAC attenuated the increase in α-
glutathione S-transferase, circulating ICAM-1 and VCAM-1 after liver 
transplantation, indicating cytoprotective effects(408). In the fifth study NAC was 
used in combination with prostaglandin E1 in paediatric liver transplant recipients. In 
this pilot study peak serum ALT was lower and median postoperative in-hospital stay 
was shorter in the treated group, while rejection was less severe(39). The most recent 
published study(211)  is a small study (9 patients each group), where NAC was 
administered (intravenously and via the portal vein) only to the donors. NAC 
administration did not affect peak transaminases or episodes of acute rejection in the 
recipients.    61
It is obvious that there is a significant variability in the results of these clinical trials. 
This could be due to differences in methodology, time and length of administration 
and primary end points. No large scale randomised trial has been performed as yet.  
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Table 2.6: NAC Experience with human liver transplantation  
 
 
NAC – N-acetylcysteine, α-GST- α-Glutathione S-transferase, PNF- Primary non function, IRI- ischaemia reperfusion injury, PGE1- Prostaglandin E1 
 
First 
Author 
n=number  of 
Patients 
Type of 
study 
Use of N-acetylcysteine  Parameters  
Bromley et 
al 
1995 
50 (25 in each 
group) 
Prospective 
randomised 
double blind  
150mg/kg NAC over 15 min followed by 50mg/kg over 4 hrs 
and 100mg/kg over 16 hours versus 5% dextrose in control 
group upon induction 
No significant differences in mortality, 
morbidity or postoperative graft function. 
Thies et al 
1998 
60 (30 in each 
group) 
Prospective 
randomised 
Liver flushed with 1L ringer lactate + NAC 1gm/l  
versus 1l ringer lactate alone for placebo & 150mg/kg NAC 
over 15 min followed by 50mg/kg over 4 hrs and 100mg/kg 
over 16 hours versus 5% dextrose in control group 
↑Portal blood flow, ↓AST & ALT in NAC 
group, ↓ need for coagulation products, 
↓ incidence of PNF and ↓ histological grade 
of severe IRI 
Steib et al 
1998 
60 (30 in each 
group) 
Prospective 
randomised 
150mg/kg NAC over 15 min followed by 50mg/kg over 4 hrs 
and 100mg/kg over 16 hours versus 5% dextrose in control 
group at time of graft implantation 
No significant differences were seen 
between the 2 groups on postoperative 
graft function or haemodynamics 
Weigand et 
al 2001 
20 (10 in each 
group) 
Prospective 
randomised  
Liver flushed with 1L ringer lactate + NAC 1gm/l  
versus 1l ringer lactate alone for placebo & 150mg/kg NAC ov
15 min followed by 50mg/kg over 4 hrs and 100mg/kg over 
hours versus 5% dextrose in control group  
↓ circulating ICAM-1 and VCAM-1 at 24 
hours after reperfusion and ↓α-GST 
 in the NAC group. No change in cytokines 
or liver enzymes 
 
Bucuvalas 
et al 2001 
25 (12 in NAC 
+ PGE1 group 
and 13 in 
control group) 
Open label 
pilot study 
IV NAC 70mg/kg upon reperfusion and thereafter 12 hourly 
for 6 days + PGE1 0.4 µg/kg/h, for 6 days 
No significant differences in mortality, 
morbidity or postoperative graft function 
Khan et al 
2005 
22 ( 9 in each 
group, 4 were 
excluded post 
randomisation) 
Prospective 
randomised 
NAC administered to donor prior to crossclamp.150mg/kg 
NAC over 15 min, followed by NAC 1gm/l in citrate for 
portal vein flush x 3 litres and NAC 1gm/L in UW during 
bench perfusion prior to organ storage 
No significant differences in mortality, 
morbidity, postoperative graft function or 
rejection episodes   63
Another interesting effect of NAC administration is the reversal of the effects of 
ischaemic preconditioning. ROS are thought be essential for the preconditioning 
response against I/R injury(190;354)  suggesting a role for ROS in redox signaling. 
Two studies found that the inhibition of ROS by NAC was detrimental to liver 
protection from ischaemic preconditioning(354;378). These findings suggest that 
small amounts of ROS are acting as signalling molecules for the body’s response 
against IRI.  
NAC has been investigated extensively in the treatment of I/R in other organs where 
it was found to ameliorate the IRI (44;83;121;211;357). Renal IRI is of clinical 
interest because of its role in renal failure and renal allograft rejection. Experimental 
studies have shown that NAC administered prior to ischaemia and immediately 
before the reperfusion period reverses I/R induced nephrotoxicity, as evidenced by 
decreases in blood urea nitrogen  and creatinine and better histology (334). This 
protective effect is associated with less oxidative stress as indicated by less lipid 
peroxidation and maintenance of GSH levels. Donor pretreatment with NAC 
preserved renal metabolism and improved outcomes of I/R injured kidney transplants 
(133;248).  
A newly designed amide form of NAC, N-acetylcysteinamide (AD4), in which the 
carboxylic group is neutralized, is more lipophilic and cell-permeating. This 
compound was shown to cross the blood-brain barrier, scavenge free radicals, chelate 
copper ions and protect mice from experimental autoimmune encephalomyelitis, a 
condition used as a animal model of multiple sclerosis and characterized by 
significant oxidative stress (289). Also AD4 protected human red cells from 
oxidative stress more efficiently than NAC (152).   64
In summary, NAC can scavenge ROS, increase glutathione levels, undergo auto-
oxidation (and produce H2O2) and serve as reducing agent. Activation of NF-κ in 
response to a variety of signals (IL-1, TNF, and H2O2) can be inhibited by NAC, 
suggesting ROS as common signalling modulators. In liver, NAC diminishes 
oxidative stress by various agents, and gives some protection against fibrosis, viral 
infections and toxicity (434).  
  NAC has been an extensively utilized tool for investigating redox sensitivity of 
biological or pathological processes. However, due to multiple activities of NAC and 
the possibility of direct modification of certain signals and signalling proteins, 
caution is warranted in interpretations. Such putative redox-sensitive mechanisms 
should be confirmed by additional approaches such as overexpression of antioxidant 
enzymes and proteins.    65
 
 
 
Chapter 3 
Glycine review   66
3.1 Introduction 
Liver IRI is characterised by series of morphologic changes, which are reviewed in 
chapter 1. Briefly, the morphologic changes include disturbances of microvascular 
perfusion secondary to injury of the sinusoidal lining signified by endothelial cells 
and Kupffer cell (KC) disturbances (47) (186), intrahepatic accumulation of white 
blood cells (WBCs) (186) and impaired hepatocellular function (47;186). Activated 
KCs have been identified as a key event in the initiation and perpetuation of the IRI. 
Activation of KC’s occurs early during organ harvest for transplantation due to insitu 
inevitable organ manipulation with standard harvesting techniques (328).These 
activated KCs are a major source of  potent mediators like reactive oxygen species 
(ROS) , tumour necrosis factor-α (TNF-α), cytokines (interleukin-6 IL-6, interleukin 
IL-8), eicosanoids and chemokines (192;369). These mediators potentially impair 
liver function by via mechanisms including disturbance of the intrahepatic 
microcirculation, hypoxia, increased oxygen consumption and depletion of 
intrahepatic glycogen reserves (331) . Activated KCs increase oxygen uptake of the 
liver after cold storage. This may be due to KC derived prostaglandin E2 (PGE2) 
which stimulates oxygen uptake in hepatocytes(174). Thus KC modulation has been 
targeted to ameliorate liver IRI either by destruction using gadolinium chloride 
(GDCL3) a rare earth metal (162) or inactivation by methylpalmitate a non 
hydrolysable fatty acid ester (263)  
3.2: Glycine  
Glycine, a non-toxic, nonessential amino acid in pharmacological doses blocks KC 
activation, along with neutrophils and possible lymphocyte activation, thereby 
providing a broad cytoprotective effect (326;441). Physiological levels of glycine 
ranges from 200-400μmol/L in humans. Glycine is a part of the normal human diet. 
The human body is able to synthesize glycine in the absence of dietary intake from   67
threonine in the central nervous system and serine in the periphery. The average 
daily diet provides up to 2 grams of glycine as it is the second most common amino 
acid found in proteins, with fish, meat and dairy products being rich 
sources(418;441). Excess glycine is catabolised by the glycine cleavage system, a 
four enzyme complex (designated as p1-4) which is present in the inner 
mitochondrial membrane and is most abundant in hepatocytes(272). The catabolic 
pathway allows consumption of glycine in energy generation by the following 
reactions(316): 
Glycine + NAD
+ + Tetrahydrofolate → CO2 + NH3  + methylene tetrahydrofolate + 
NADH + H
+ Methylene tetrahydrofolate  + Glycine → Serine 
Serine → Pyruvate → Acetyl phosphate → ADP → ATP + Acetate 
 
3.3: Mechanism of action of glycine 
The cytoprotective and anti-inflammatory effect of glycine depends on the structural 
characteristics , which glycine shares with other amino acids like taurine, alanine and 
strychnine (411).  
Glycine is an inhibitory neurotransmitter in the central nervous system where it 
hyperpolarizes the post synaptic spinal motor neurons and has been used 
therapeutically in central nervous system disorders(35;237).  Weinberg et al first 
reported the cytoprotective effect of glycine during the investigation of the 
mechanism of antioxidant glutathione and it’s constituent amino acids(409). This 
cytoprotective effect was independent of cellular ATP levels 
Glycine inhibits nonlysosomal calcium dependant proteases and protects hepatocytes 
against anoxic damage(441). Ozaki et al demonstrated that glycine could protect 
livers in situ from reperfusion damage by minimising lipid peroxidation (295).   68
Glycine could stabilise the cell membrane by inhibiting phopholiase A2 , leading to a 
reduction of arachidonic acid and eicosanoids which influence hepatic 
microcirculation(332).Carolina rinse solution which contains glycine prevents 
reperfusion injury to livers in both experimental and human liver transplantation(14). 
The protective effect of glycine is mediated via mechanisms involving 
proinflammatory mediators, hypoxia reduction, reperfusion enhancement and toxin 
attenuation in various animal species (154).   Glycine has been shown to inhibit KC 
activity when administered either orally or intravenously (326;327). 
3.4: Glycine receptors 
The anti-inflammatory and cytoprotective effects of glycine are mediated via glycine 
receptors (GlyR). GlyR stimulation produces hyperpolarization of cell membrane by 
Cl
- influx and consequent inhibition of excitation under inflammatory stimuli(254). 
GlyR were originally discovered in the CNS, where glycine acts as an inhibitory 
neurotransmitter(254), later GlyR were found to be present on peripheral cells(91). 
3.4.1: CNS glycine receptor 
GlyR are primarily localised to the post synaptic membrane in the spinal cord, brain 
stem, caudal brain and in the retina where they mediate reciprocal inhibition 
necessary for spinal cord reflexes and muscle tone(254). In the brain, glycine acts as 
the principal mediator of fast inhibitory neurotransmission. Activation of the anionic 
(Cl
- and bicarbonate) channels by glycine and gamma amino butyric acid 
respectively causes post synaptic membrane hyperpolarization and suppression of 
neuronal firing(36). 
3.4.2: Peripheral glycine receptor 
Peripheral GlyR are present in almost all cell types including white cells i.e. Kupffer 
cells (KC) (130;180), alveolar macrophages(130), splenic macrophages(130),   69
Monocytes(360), Neutrophils(130;417), lymphocytes(361), epithelial cells such as 
hepatocytes(309) and endothelial cells(428;438). The structure of peripheral GlyR is 
similar to the central GlyR. Molecular evidence for the presence of GlyR on 
peripheral cells is based on demonstration of mRNA and protein expression of GlyR 
subunits in KCs, alveolar and splenic macrophages and neutrophils(130). Yamashina 
et al demonstrated evidence for GlyR β subunit on endothelial cells using western 
blot analysis(428). 
Functional evidence for the effects of glycine in peripheral inflammatory cells has 
been demonstrated by amelioration of TNF-α (180;360;420), IL1-β(360) ,IL-
10(360), decreased production of oxygen derived free radicals(417;420). In addition 
glycine prevents the apoptosis of cultured sinusoidal endothelial cells (SEC) caused 
by deprivation of the vascular endothelial growth factor (VEGF) possibly by a Bcl2 
dependant mechanism, since the fall in Bcl2 induced by VEGF deprivation is totally 
prevented by glycine. This effect is also mediated by GlyR as it is prevented by low 
dose 1mM strychnine, an antagonist of glycine at low doses(438). 
3.5: Mechanism of anti-inflammatory action of glycine 
Intracellular calcium is mostly sequestered in the endoplasmic reticulum, keeping the 
concentration of cytoplasmic calcium low while the extracellular fluid has a 
relatively higher concentration of calcium(28;120). Mammalian cells express two 
types of Ca
+2 channels viz. voltage gated and receptor gated. Cell injury leads to an 
increase  in intracellular calcium flux by opening of voltage gated Ca
+2 channels 
which in turn are activated by membrane depolarization (267;391;395). Activation of 
these channels allows cytoplasmic influx of Ca
+2 along the concentration gradient 
and glycine prevents this rise in intracellular Ca
+2  (417;420). This is achieved by 
stimulating chloride ion (Cl
-) conductance by activating GlyR which increases   70
intracellular Cl
-1and thus hyperpolarizes the cell membrane preventing depolarization 
in response to inflammatory stimuli and preventing activation of voltage gated Ca
+2 
channel activation.(180;417). 
Besides membrane hyperpolarization, several other studies have proposed other 
modes of action for glycine. Inhibition of Ca
+2 dependent degradative, nonlysosomal 
proteases, including calpains following recovery of intracellular pH after 
reperfusion(282), KC membrane stabilization by suppressing changes in plasma 
membrane proteins(210) and inhibition of  an organic anion channel(154). 
3.6: Cytoprotective effect of glycine 
The cytoprotective effect of glycine has been shown to be independent of Ca
+2 
homeostasis and Cl
-1 conductance in cultured cells(111;136;410) while others have 
suggested a role for Cl
-1Channel blockade in cytoprotection(274)  suggesting that the 
basis of this effect needs further clarification. Calcium has been shown to be the final 
common pathway leading to cell death induced by toxic influences(324)and 
increased intracellular Ca
+2 is a common feature between apoptotic and necrotic cell 
death(392). Glycine can provide cytoprotection despite allowing a rise in 
intracellular Ca
+2 ; a effect which is probably mediated by blocking pre lytic opening 
of large cell membrane pores (death channels) and hence preventing cell lysis. In 
addition glycine also prevents the cell membrane bleb dilatation in response to 
increasing membrane permeability(284). 
Hepatic IRI leads to cellular ultra structural changes like development of vesicular 
profile, alteration of junctional complexes and development of electron 
densities(129). Cell swelling and bleb formation has also been described in 
hepatocytes after cold and warm ischaemia(46;242). Similar cell membrane 
blebbing, followed by bleb dilatation and cell lysis has been shown to occur in a   71
variety of invitro models of cellular injury and these models have been used to study 
the cytoprotective effect of glycine(48;95;96;111;284). The cytoprotective effect was 
found to be independent of the calcium flux although glycine did delay the rise in 
intracellular calcium but did not prevent it completely. This cytoprotective effect of 
glycine has been shown to depend on it’s effect at the cell membrane rather than it 
being a intracytoplasmic action.(97)   72 
Table 3.1: Mechanisms of action of glycine 
  Cytoprotective effect  Modulatory Effect 
Cells most studied 
Renal cells 
Hepatocytes 
Endothelial cells 
Immune cells 
Macroglial Cells 
Endothelial Cells 
Main effect  Protection against ischaemic necrosis  Modulation of proliferation, migration, apoptosis 
Active concentrations  Upto 10 mM  0.1-1 mM 
Ca
+2 Flux modulation  No Yes 
Uptake of Chloride  No Yes 
Chloride dependency  No Yes 
Molecular Findings  Only β subunits  Both α & β subunits 
Suggested Mechanism 
Glycine sensitive death pathway.  
Unknown role of GlyR 
GlyR dependent modulation of calcium signalling 
Pharmacological Findings 
Effects mimicked by related amino acids but 
not by taurine 
Effects mimicked by taurine and β-alanine 
 
Key: Ca
+2 = calcium, α = alpha, β = beta, GlyR= glycine receptor   73
3.7: Glycine and hepatic ischaemia reperfusion injury 
In the liver IRI is a serious problem after liver transplantation and complex 
resectional surgery which may lead to liver dysfunction and poor outcome. Thus, a 
nonessential amino acid like glycine with its cytoprotective and anti-inflammatory 
properties might provide just the solution for this problem. Glycine specifically acts 
on KCs and Neutrophils, which play a central role in initiating and sustaining the 
IRI. The protective effect of glycine on IRI has been demonstrated in a wide variety 
of models of ischaemic injury either in cell culture experiments or in vivo in various 
different animal models. 
3.7.1: Effect of glycine on cell culture models 
 Glycine has been shown to prevent injury to both cultured hepatocytes and SECs 
from the effects of hypoxia, toxins and potassium cyanide (KCN) (53;81;285). ATP 
depletion by KCN induces proteolytic activity, in cultured hepatocytes which is a 
possible mechanism of cell death(94).Glycine has been shown to reduce this 
proteolytic effect in a dose dependent manner which corresponds to it’s 
cytoprotective effects(94;119;282). Mitochondrial permeability transition (MPT) has 
been proposed as a mechanism for loss of cell viability after reperfusion(308). In this 
process large pores open in the mitochondrial inner membrane  which conduct both 
positively charged and negatively charged particles leading to mitochondrial 
depolarization and decoupling of oxidative phosphorylation(285;308).Glycine has 
been shown to improve cell viability without any effect on return of intracellular pH  
towards normal after reperfusion and MPT to occur(284). This would suggest that 
the effect of glycine is downstream of MPT and ATP generation(308).There are 
conflicting reports on the intracellular changes in cultured hepatocytes. Glycine 
prevented the intracellular accumulation of Na
+1 associated with KCN or hypoxia 
induced ATP depletion in cultured hepatocytes preventing cell lysis(53). The   74
proposed mechanism being inhibition of Cl
-1 entry into the cell which normally 
precedes Na
+1 influx. Glycine has also been demonstrated to inhibit stress induced 
accumulation of intracellular Ca
+2 thus preventing cell death(309).In cultured SECs 
glycine acts by blocking glycine sensitive large pores thereby preventing anoxic cell 
death in as yet incompletely understood manner(284). 
3.7.2: Glycine and isolated liver perfusion 
Several liver perfusion models have shown beneficial effects of glycine(81;327;440). 
den Butter et al have shown better cold preservation with UW solution than when 
glutathione was replaced  with glycine in a isolated perfused rabbit liver after 48 
hours of cold preservation. This effect was only found with cold preservation, 
however when glycine was added to the reperfusion medium it significantly reduced 
hepatocellular injury (90). Currin et al  reperfused UW stored liver with Krebs-
Henseliet buffer alone (KHB) Buffer + glycine or Carolina rinse solution. 
KHB alone liver demonstrated extensive endothelial cell death, while KHB + glycine 
or Carolina rinse solution showed equivalent benefit.(81). Zhong et al have shown 
glycine to be beneficial in low flow reflow model of liver circulation where low flow 
caused pericentral hypoxia and normoxic periportal areas. Reflow produced injury in 
the periportal areas which was ameliorated by glycine (440). However, it is 
impossible to extrapolate this data to the clinical scenario because of the limitations 
of extracorporeal perfusion models like non physiological perfusates, temperature 
and haemodynamics. 
3.8: Experience with animal liver transplantation 
Glycine has shown significantly reduced hepatocellular injury with improved 
survival in various animal models(14;24;89;90;315;326;436). Glycine has been 
administered both orally as well as intravenously to the donor or recipient, as a part   75
of preservative solution, during cold preservation or as a part of pre-reperfusion flush 
solution and in perfusate during insitu normothermic reperfusion and before cold 
preservation in non heart beating donor model. den Butter et al have reported 100% 7 
day survival with use of glycine in preservative solution instead of 
glutathione(90).Similar results have been reported with the use of glycine in Carolina 
Rinse Solution( CRS) but not when either were used alone(14). Schemmer et al have 
shown that operative manipulation during liver retrieval initiates a KC based 
inflammatory cascade which is ameliorated by oral glycine administration to the 
donor. An equivalent benefit was seen when glycine was administered intravenously 
(326). Zhang et al have shown improved viability of the liver of the brain-death 
donor rat after pretreatment with glycine (436), while Benko et al have more recently 
shown decrease of liver injury and improvement of liver function after pretreatment 
with  oral glycine for 5 days in a rat model of partial hepatectomy (24). Rentsch et al 
showed better perfused sinusoids with reduced neutrophilic infiltration in livers 
obtained from donor rats administered glycine with significantly better survival as 
compared to control, gadolinium chloride or methylpalmitate groups. This study is 
important since it shows that glycine ameliorates both the early and late phase of 
liver IRI as reviewed in chapter 1(315) 
3.9: Glycine and human liver transplantation 
There is limited clinical experience with the use of glycine in human liver 
transplantation; however, glycine has shown promise in reducing the hepatic IRI. 
The various clinical trials using glycine in liver transplantation are summarised in 
Table 3.2.   76 
Table 3.2: Experience with Glycine in human liver transplantation: 
  
 
First Author  No  of 
Patients 
Type of study  Use of glycine  Parameters   Complications 
Glycine 
group 
Control group 
Arora  (7)  50  Double Blind 
Randomized 
Controlled trial 
Hepatic arterial (150 ml) and portal vein (350 ml) flush of 
2mM glycine solution before reperfusion 
↓ALT day 1-3 
post OLT 
ITBS 1 
patient 
ITBS 4 patients 
Re-transplant 3 in 
6-8 months 
Schemmer (329)  4  Controlled 
observation 
study 
300 mM, 250 ml glycine infusion over 1 hour before 
reperfusion and than daily for 1 week post OLT 
↓ALT (24 
hour) and 
AST(48 hour) 
peaks
‡ 
No PDF  PDF 11% 
Schemmer (330)  7(includes 
from above 
study) 
Controlled 
observation 
study 
300 mM, 250 ml glycine infusion over 1 hour before 
reperfusion and than daily for 1 week post OLT 
↓ALT (24 
hour) and 
AST(48 hour) 
peaks
‡ 
-- -- 
 
‡, significant (P<0.05) vs historical controls 
PDF, primary dysfunction 
ITBS, ischemic type biliary stricture 
, reduced 
            Values not published 
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In a prospective double blind randomised controlled trial involving 50 patients, dual 
vessel rinse with glycine solution through the hepatic artery and portal vein prior to 
reperfusion significantly reduced ALT rise for 3 days post OLT(Orthotopic liver 
transplantation) and reduced incidence of ischaemic type strictures and overall 
morbidity(7). Schemmer et al also reported similar results in a study of glycine in 
human liver transplantation. They administered 250 mls of 300mM glycine infusion 
over 1 hour before OLT and then daily for 1 week post OLT. Their patient group 
were matched with historical control, however the historically matched controls had 
11% incidence of primary graft failure, while there were none with glycine pre-
treatment(329;330). Although the study designs of these two latter studies were not 
robust, their results admittedly suggest some benefit without significant side effects. 
3.10: Dosage and clinical safety of glycine  
The normal daily diet contains approximately 2 grams of glycine, but up to 40-
90gm/day has been used for up to 6 weeks, in clinical trials without any serious 
adverse effects(169). This high dose oral intake resulted in increased blood levels to 
more than 3 times normal values of 300μM. Schemmer et al have used 250ml 
infusion of 300mM glycine administered over 1 hour in liver transplant 
recipients(329). This infusion increased serum glycine levels to 1952±210 μM. The 
half life of glycine after intravenous infusion or body cavity irrigation depends on the 
dose administered and can vary between approximately  half an hour up to 4 
hours(155). 
Oral treatment with glycine, is well tolerated with only minor side effects like 
nausea, vomiting and upper abdominal discomfort have been reported.These too 
have resolved following cessation of therapy(169). Similarly high dose intravenous   78
glycine administration for 4 days in a study of it’s availability in healthy volunteers 
did not report any serious adverse effects (84). 
3.11: Glycine Toxicity 
Although oral and intravenous glycine usage has been not associated with serious 
side effects, the following reports of glycine toxicity are mentioned in the literature 
following its use as an irrigant solution. 
Glycine 1.5% solution when used as an irrigant in urological and gynaecological 
procedures may be absorbed through cut venous sinuses. Systemically absorbed 
glycine is primarily metabolised by transamination to serine, and by deamination to 
ammonia, which is normally removed by its conversion to urea. A portion of the 
absorbed glycine is excreted by the kidneys. Absorption of large amounts of 
irrigating solution can also result in pronounced hyponatremia and water intoxication 
(183). Absorption of this solution has also reportedly been implicated with 
neurotoxicity, cardiotoxicity and nephrotoxicity(137;183;255). 
Increased serum concentration of ammonia following glycine administration would 
predispose patients with pre-existing impaired hepatic function to encephalopathy. 
The two neurotoxic metabolites of glycine (Glyoxylic acid and glycolic acid) 
increase after glycine administration.(255).Transient cardiac arrhythmias and even 
cardiac arrest have been reported following the use of glycine as an irrigant in 
urological and gynaecological procedures(42;137). 
Fibrinolysis and minor haemolysis has also been reported following use of glycine as 
an irrigant, which may be due to osmolar changes or due to direct effect of 
glycine(183). Similarly hyperoxaluria following glycine use as an irrigant may affect 
renal function particularly in event of hypovolemia and oliguria(8;123)   79
High concentration of glycine in preservation solution may be lead to anuria(256), 
while Olsson et al found that infusion of 1.5% glycine solution increased mortality in 
mice, independent of it’s effect on osmolality(293). 
In conclusion there is good molecular evidence for the presence of glycine receptors 
in peripheral macrophages with considerable evidence towards it’s mechanism in 
hepatic IRI. There is however little evidence of the effect of glycine on portal blood 
flow, bile flow and biliary composition and cytokines like IL-8 which are responsible 
for the initiation and maintenance of the latter phase of liver IRI.  
Hence in this thesis we propose to use a well established animal model of partial 
lobar liver IRI to study the effects of a single dose of IV glycine adminstered prior to 
the ischaemic injury and its effect on liver microcirculation, hepatic mitochondrial 
activity, bile flow and composition, portal blood flow, cytokine expression (TNF-α 
and IL-8) and serum ALT and AST. We propose to use 1 hour of ischaemia and 6 
hours of reperfusion in order to understand the changes in both the early phase and 
initial part of the late phase of liver IRI. In addition in order to assess the effect of 
ROS on liver IRI we propose to use NAC prophylactically within a randomised 
double blind controlled clinical trial for all patients undergoing elective liver 
resection. The next chapter describes the animal model used including the various 
animal groups and the materials and methods used in the various studies in the thesis   80
 
 
 
Chapter 4 
Animal model, materials and methods 
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 4.1 Animal model of lobar liver I/R injury 
This study was conducted under a license granted by the home office in accordance 
with the Animals (Scientific Procedures) Act 1986. New Zealand white rabbits (3.2 ± 
0.4Kg, n=18) were used for the experiments. All animals were kept in temperature 
controlled environment with 12-hour light-dark cycle. Animals were kept without 
food overnight prior to the experiments. The hospitals ethics committee approved the 
experimental research protocols. 
  Anaesthesia was induced by an intramuscular injection of 0.5ml/kg of fentanyl 
citrate and fluanisone (Hypnorm; Janssen Animal Health , Buckinghamshire, UK). 
Folllowing tracheostomy anaesthesia was maintained with isoflurane (1.5-3%) 
through an anaesthetic circuit. Body temperature was maintained at 37-38
oC by a 
warming blanket (Homeothermic blanket control unit; Harvard Apparatus, 
Southmatick, Massachussets, USA) and monitored with a rectal temperature probe. 
Haemoglobin oxygen saturation and heart rate were continuously monitored and 
recorded by a pulse oximeter (Ohmeda Biox 3740 pulse oximeter; Ohmeda 
Louisville, Colorado, USA). Ear marginal vein was cannulated with radioopaque 
catheter 20 gauge for administration of fluids, anaesthetics, and blood sampling. Ear 
marginal artery was cannulated with a 20 gauge radioopaque catheter and connected 
to a pressure transducer for monitoring the mean arterial blood pressure. 
After induction of anaesthesia a midline laporotomy was performed. The 
ligamentous attachments of the liver were divided and the liver was exposed.The 
rabbit liver is divided in left and right regions by a deep cleft with the right and left 
lobes further divided into anterior and posterior lobules.as depicted in figure 4.1 
There is a quadrate lobe, which is behind the gallbladder. Lastly, there is a small 
circular lobe called the caudate lobe next to the right kidney. The gallbladder is deep   82
within the abdominal cavity. There are separate openings for the bile duct and 
pancreatic duct into the duodenum.  
Figure 4.1: Rabbit liver displaying the lobar anatomy 
 
 
Lobar ischaemia was induced by clamping the vascular pedicles of the median and 
left lobes of the liver, using an atraumatic microvascular clip. This method produces 
a severe ischaemic insult without causing mesenteric venous hypertension(225). 
After 60 minutes of ischaemia the vascular clip was removed and reperfusion 
allowed for upto 6 hours. At the end of the experiment the animals were killed by 
exsanguination.  
Hepatic microcirculation was continuously measured via a probe placed on a fixed 
site on the median lobe of the liver and held in place by a retort holder during 
ischaemia and reperfusion period. Hepatic tissue oxygenation was continuously 
measured via optodes placed on the surface of the left liver lobe during ischaemia 
and reperfusion period     83
The portal vein flow was monitored continuously using a 3mm transonic Doppler 
flow probe (Transonic Medical Flowmeter system, HT207; Transonic Medical 
System, Ithaca, New York, USA). 
4.2 Experimental groups and protocol  
Three groups of animals were used (n=6) in each group. Sham group of animals 
underwent anaesthesia and laparotomy but no ischaemia or reperfusion was induced. 
The Control group had 1 hour of ischaemia and 6 hours of reperfusion and the 
Glycine group, which received an additional 300mosm of glycine given 
intravenously at a dose of 5ml/kg body weight prior to induction of ischaemia by 
slow intravenous infusion over 15 minutes. An equivalent volume of normal saline 
was injected in the control group of animals. 
4.3 Hepatic microcirculation 
Hepatic microcirculation (HM) was measured by a surface laser Doppler flowmeter 
(LDF) (DRT4, Moor Instruments limited, Axminister, UK) in flux units. LDF is an 
established method of measuring tissue microcirculation continuously in an easy way 
that does not interfere with blood flow to the tissues(4;415;416). 
A monochromatic laser light was generated from a 2mV- helium neon laser at 632nm 
and delivered to the tissues via optical fibres. The light reflected back from the 
tissues was carried back through the optical fibres and detected by a photo 
detector.Only the photons which are scattered by moving red blood cells (RBC’s) 
will have a Doppler frequency shift unlike those reflected back from static tissues. 
Mixing of these two components by the photo detector generates an electrical signal 
that contains the Doppler frequency shift information. This electrical signal is further 
processed to produce an output voltage that is related in a linear fashion to the total 
number of moving RBC’s in the area in cubic millimetres multiplied by the mean   84
velocity of the RBC’s. Linearity of the LDF signal from the liver with total organ 
perfusion has been demonstrated and the technique has been shown to be sensitive to 
rapid changes in organ blood flow.(4;145;335;415).  
The LDF measures flow in arbitrary perfusion unit (flux), a quantity proportional to 
the product of the average speed of the blood cells and their number concentration 
(often referred to as blood volume). This is expressed in arbitrary ‘perfusion units’ 
and is calculated using  
Flux = Cmrbcs x Vmrbcs 
where,  Cm = concentration, Vm = Velocity of RBC’s (red blood corpuscles) 
 Due to the variation of the signal across the surface of tissues it is not possible to 
apply a conversion factor that so that the LDF signal can be expressed in absolute 
flow units(4;415). The application and reproducibilty of LDF measurement for 
assessment of liver microcirculation has been validated in both experimental animals 
and human liver transplantation (335;336;416). 
Hepatic microcirculation was assessed using a commercially available dual channel 
surface laser Doppler flowmeter (DRT4, Moore instruments Ltd., Devon, UK) 
(Figure 4.1). 
At the start of each study the LDF was calibrated against a standard reference 
(Brownian motion of polystyrene micro-spheres in water) provided by the 
manufacturer. In order to curtail any disturbance to blood flow due to the pressure 
exerted by the LDF probe on the hepatic surface, the probe was attached to a probe 
holder so that the probe itself was just in contact with the hepatic surface without 
applying any pressure by the probe weight. The probe was applied to same point in 
all experiments in order to minimise any error due to anatomical variations in the 
hepatic microcirculation.   85
Data from the LDF was recorded and collected continuously.The LDF data was 
collected   before the application of ischaemia as baseline and at end of 1 hour of 
ischaemia, and at 1,2,4 and 6 hours after onset of reperfusion as a mean of 2 minute 
data   86
 
 
 
 
 
 
 
Figure 4.2: Dual channel surface laser Doppler flowmeter and its probes (DRT4, 
Moor Instruments Ltd., Devon, UK).   87
4.4: Intracellular oxygenation/mitochondrial activity 
Cytochrome oxidase activity as a reflection of intracellular oxygenation was 
continuously measured using near infrared spectroscopy (NIRS). In all tissues a 
number of colour bearing compounds (chromphores) viz Oxyhaemoglobin (HbO2), 
Deoxyhaemoglobin (Hb) and cytochrome oxidase (CytOx) are present in variable 
concentrations. They have different absorption spectra in the near infrared (NIR) 
light and their absorption characteristics are oxygen dependent (101;102). 
CytOx is the terminal complex of the mitochiondrial respiratory chain(49). It takes 
electrons from the cytochrome C and catalyses the reduction of oxygen to water with 
the concommitant synthesis of ATP through the oxidative phosphorylation 
process(50) (101). In hepatocytes, approximately 90% of the oxygen is consumed by 
mitochondrial cytochrome oxidase. CytOx contains four redox active metal sites: two 
haem iron (Haem a and Haem a3) centres, the copper-copper dimer (CuA) and the 
binuclear Haem-copper coupled centre (haem a3/Cuβ). These four metal centres 
accept or donate electrons during electron transfer through the respiratory chain, 
changing their redox state. The oxygen binding site of the enzyme is the binuclear 
unit formed of the Cuβ and Haem a3. The donation of electrons from this unit to 
oxygen accounts for the majority of oxygen consumption in the tissues. The CuA and 
haem a centres donate electrons to the binuclear unit and therefore are not directly 
involved in oxygen reduction (49;50;101). In the absence of oxygen, electron transfer 
to oxygen cannot take place. Electrons accumulate on the haem and copper atoms 
and CytOx becomes reduced. With oxygen availability the electrons are rapidly 
transferred from the metal centres to oxygen and CytOx becomes oxidised. Many 
factors can affect the CytOx redox state in vivo, but the most significant factors are 
the oxygen concentration (50;73), nitric oxide in physiological circumstances and 
oxidants such as ROS and RNS in oxidative stress situations(349;350).   88
All four centres exhibit different absorption characteristics dependin on their redox 
state. The copper centres are optically sensitive in the NIR region in contrast with the 
haem centres that absorb visible light(50;73). Absorption of the NIR light by CytOx 
occurs primarily at the CuA centre within the CytOx. The oxidised CuA centre has a 
characteristic shape spectrum with a broad peak centred around 845nm (50;73). The 
signal intensity decreases on reduction of this centre. The contribution of haem iron 
centres to absorption of NIR is less than 10% of the total signal in the reduced-
oxidised spectrum(50;73). 
The redox state of CytOx CuA  is dependent on cellular oxygen availability 
(50;74;99;371).  In the presence of oxygen electron transfer occurs and the enzyme 
becomes oxidised whereas lack of oxygen results in a decreased flow of electrons 
and CytOx becomes reduced. The increase in the reduction state of CytOx reflects 
severe cellular hypoxia.  
4.4.1: Basic principles of NIRS  
Biological tissues interact with light in a multitude of ways including scattering, 
reflection and absorption which is dependant on the type of tissue illuminated and the 
wavelength of light used (101). Light in the visible range of the spectrum (450-
650nm) is strongly attenuated due to its absorption by haemoglobin and its scattering 
in tissues. This attenuation is inversely related to the wavelength of light. This leads 
to the failure of light to penetrate for more than 1cm into tissues (101;218). However, 
the NIR region of the electromagnetic spectrum (700-1000 nm) represents an optical 
window of relative transparency and a significant amount of radiation can be 
effectively transmitted through biological materials over distances of upto 8 
cms(101;218). 
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Figure 4.3: Absorption spectra of HbO2, Hb, and Cyt Ox in the NIR light 
region(201)   90
 
 
NIRS depends on two basic principles;  
1)  The relative transparency of biological tissues to light in the near infrared 
region of the spectrum. 
2)  The existence of different tissue chromophores with characteristic absorption 
spectra in the NIR light spectrum(101;294;387).  
In tissues with homogenous scattering the calculation of light attenuation and the 
relationship between the optical absorption and chromophore concentration may be 
described by a modified Beer-Lambert’s law. The law modifications include: 
1)  an additive term, G, due to scattering losses and  
2)  a multiplier , to account  for the increased optical pathlength due to scattering. 
This law can be used to convert the obtained optical densities to concentration of 
CytOx in μmol/L per optical pathlength (75;101;425):  
A= α.c.d. B+ G 
Where A is the attenuation of light, α is the absorption coefficient of the 
chromophores (µmol
-1.cm
-1), c is the concentration of the absorption compound 
(µmol/L) and d is the distance between the entry and exit points of light into the 
tissues (cm). B is the differential path length factor (DPL) which accounts for the 
increase in optical path length due to light scattering (which causes the optical path 
length to be greater than d) and G is a constant factor which accounts for loss of 
photons by scattering. As G cannot be quantified in vivo and is dependent upon the 
scattering coefficient of the particular tissue, it is not possible to measure the 
absolute concentration of the chromophore in the tissue from measurement of the 
absolute attenuation. If , B, and d are known and G assumed to remain constant 
during measurement, we can measure the change in the chromophore concentration 
(c) from measuring the change in attenuation (A) from the following formula:    91
c = A / . d. B. Since the absolute concentration of tissue chromophores are 
unknown and cannot be calculated due to the effect of light scattering within the 
tissue, all NIRS measurements are expressed as absolute concentration changes 
(mole/L) from an arbitrary zero at the start of the measurement. The absorption 
coefficient of Cyt Ox was obtained in vivo by replacing the blood in the brains of 
experimental animals with a blood substitute (fluorocarbon) and exposed to 100% O2 
or N2 to obtain the oxidised and reduced Cyt Ox spectra (75;101;425). B depends on 
the amount of scattering in the medium which can be measured by “the time of flight” 
method(88).  
For simultaneous calculation of the changes in concentration of a number of 
chromophores from changes in attenuation at a number of wavelength, an algorithm 
can be used which incorporates the relevant absorption coefficient for each 
chromophore at each wavelength(75;99).  
4.4.2: Near Infrared Spectrophotometer 
The NIR spectrophotometer used in this study is the NIRO-500 (Hamamatsu 
Photonics K.K, Hamamatsu, Japan) (Fig2.). This spectrophotometer is the 
commercial version of an instrument developed by colleagues in the department of 
Medical Physics and Bioengineering, University College London (75;99). In the 
NIRO 500, the light source is monochromatic, generated from semiconductor laser 
diodes(LD). The light is produced at four wavelengths (774,826,849,906 nm). The 
choice of the wavelengths is based on 765nm, the absorption maximum for Hb; 
810nm the isobestic wavelength at which the extinction coefficients of HbO2 and Hb 
are equal which can be used to calculate haemoglobin concentration independent of 
oxygen saturation; 845nm, the absorption maximum for oxidised Cyt Ox; and 
900nm, a reference wavelength(99;425)   92
The light is produced by laser diodes and carried to the liver via a bundle of optical 
fibres in sequential pulses. The optical fibres are covered by a light proof protective 
sheath and it’s distal end terminated in a very small glass prism which reflects the 
light through 90
o to direct it into the tissue(294). Photons emerging from the liver are 
collected by the second bundle of optical fibres and detected by a photomultiplier 
tube(PMT) light detector(294) (Figure 4.3). The incident and transmitted light 
intensities are recorded and from these the changes in the concentration of tissue 
chromophores (µmol/l) are calculated using an algorithm incorporating the known 
chromophores absorption coefficients and an experimentally measured optical 
pathlength.   93
 
 
 
 
 
Figure 4.4: Near infrared spectrometer probes and a rubber optode holder (NIRO 
500, Hamamatsu Photonics KK, Hamamatsu, Japan)   94
The standard NIRO 500 algorithm was developed using the wavelength dependant 
pathlength for the brain tissue (110). As a part of this study , modification of the 
NIRO 500 algorithm has been carried out in the department of Medical Physics and 
Bioengineering, University College London for it’s hepatic application(99;101). The 
absorption coefficient of a freshly dissected and viable blood free pig liver was 
measured. The absorption coefficient was found to be 0.04mm
-1 at 800 nm which is 
four times larger than that of normally perfused brain tissue although the transport 
and scattering coefficient was similar at 1.0mm
-1. When the absorption coeffient of 
blood in a normally perfused liver was added to the blood free absorption coefficient, 
the overall absorption coefficient was near 0.1mm
-1 with the scattering coefficient 
essentially unchanged. The optical pathlength as a function of wavelength for 
normally perfused liver was then calculated incorporating the measured absorption 
coefficient and the scattering coefficient mathematically corrected for the 
contribution of haemoglobin absorption. The average blood content in the liver was 
assumed to be 12% by volume  at an average haemoglobin saturation of 60%(238). 
4.4.3: NIRS application in the rabbit, data collection, Analysis 
NIRS probes were mounted inside a probe holderand placed on the liver surface at a 
fixed site of the left lobe of the liver in all the animals in each experiment to avoid 
any anatomical variation, which could influence tissue oxygenation and blood 
volume. A flexible rubber holder was made to hold the NIRS probes at a fixed 
spacing over the liver surface. This probe holder ensured that the sites of light entry 
and exit are maintained at a constant and known spacing distance, which would 
minimise artefacts secondary to changes in the distance between the probe ends and 
allow as a satisfactory contact between the liver surface and probe ends 
The NIRS spectrometer has the facility to set the attenuation and therefore 
chromophore concentration changes were set to zero with the initial NIRS setting.   95
This function is important so that all measurements are from a initial arbitrary zero, 
which ensures that artefacts such as system drift, optode movement and excessive 
light have a minimal effect on the data. A laptop computer connected to the NIRS 
spectrometer continuously collected the NIRS data. The data essentially are the 
changes in light attenuation (optical densities: OD) at four wavelengths due to 
absorption by the tissue chromophores. A software program called ONMAIN
® 
(Hamamatsu Photonics K.K, Hamamatsu , Japan) was used to convert these data into 
changes in concentration of Cyt Ox (µmol/l) using the previously defined algorithm 
in the NIRO 500. This data was then transferred to excel
® data sheets (Microsoft 
Corporation, Seattle, USA) for analysis. The data was collected at the relevant time 
points as mean of 2 minute measurements and calculated in regard to the baseline 
value (zero set at start of experiment).   
4.4.4: Interpretation of NIRO 500 measurement 
NIRS allows continuous monitoring of the changes in Cyt Ox. Measurement of  
CytOx redox state provides a good index of intracellular oxygen. Cyt Ox becomes 
more reduced with decreasing the blood flow or oxygen saturation and more oxidised 
with increasing the blood flow, or oxygen saturation(34;48;73). Changes in the level 
of glucose, as a substrate for the electrons generated in the respiratory chain, also 
affects the redox state of Cyt Ox. With hypoglycaemia Cyt Ox becomes more 
oxidised and with glucose administration it becomes more reduced (34;48;73). The 
cell metabolic activity can affect the redox state of Cyt Ox, with increasing metabolic 
activity, it becomes more oxidised providing that adequate oxygen and substrate are 
available (73;101;145).   96
4.5: Ultrasonic transit time flowmetry 
In this study blood, flow through the PV (PVBF) was measured using ultrasonic 
transit time flowmetry. 
4.5.1: Principle of ultrasonic transit time flowmetry 
Using wide-beam illumination, two transducers pass ultrasonic signals back and 
forth, alternately intersecting the flowing liquid in the upstream and downstream 
directions. The transit time of such beam is a function of the volume flow 
intersecting this beam, regardless vessel dimensions or cross-sectional area. In the 
same way that a swimmer will move quicker in the downstream direction than in the 
upstream direction, the speed of the ultrasound is affected by the flow of liquid 
passing the ‘acoustic window’ of the flow probe. The flowmeter derives an accurate 
measure of the transit time it took the wave of ultrasound to travel from one 
transducer to the other. The difference between the upstream and downstream-
integrated transit times is a measure of volume flow rather than velocity(337;372). 
The ultrasonic transit time flowmetry has been demonstrated to provide an accurate 
method for hepatic blood flow measurement(11;197;346). 
4.5.2  Ultrasonic transit time flowmeter 
PVBF, was measured continuously using a dual ultrasonic transit time flowmeter 
(HT207, Transonic Systems Inc, NY, USA) (Fig 2.4.1) . The flowmeter perivascular 
probes was placed around the portal vein. The accuracy of this technique is 
dependent on careful positioning and alignment of the probe with respect to the 
vessel. The vessel should be positioned within the central area of uniform ultrasonic 
intensity of the probe window i.e. away from the probe window edges, which have 
lower ultrasonic beam intensity (372). Also, it requires accurate selection of the 
probe size which was determined by the outer diameter of the blood vessel.   97
4.5.3 Ultrasonic transit time flowmeter data collection and analysis 
Data from the continuous measurement by the ultrasonic flowmeter were collected 
via the NIRS program. After conversion of the NIRS data to excel sheets, the 
ultrasonic flowmeter data at the relevant points was calculated as a mean of 1-minute 
data.   98
 
 
 
 
Figure 4.5: Dual ultrasonic transit time flowmeter (HT207, Transonic Systems    
Inc., NY, USA) and the perivascular probes.   99
4.6: TNF-α ELISA  
For the TNF-α ELISA (BD Pharmingen, Oxford, UK) the primary antibody (capture 
antibody) was a purified goat anti-rabbit TNF-α and the secondary antibody 
(detection antibody)  a biotinylated goat anti-rabbit TNF-α antibody. Both the 
antibodies were titrated to determine optimal concentrations for ELISA capture and 
detection. To obtain linear standard curves doubling dilutions of recombinant rabbit 
TNF-α protein ranging from 10,000 – 80 pg/ml were included in each ELISA plate. 
4.7:  IL-8 ELISA  
For the IL-8 ELISA an OptEIA
TM Rabbit IL-8 set (BD Pharmingen, Oxford, UK) 
was used. The set contained an anti-rabbit IL-8 antibody for capture and a 
biotinylated anti-rabbit IL-8 antibody as a detection antibody. To obtain linear 
standard curves doubling dilutions of recombinant rabbit IL-8 ranging from 200-0 
pg/ml were used. All ELISA’s were performed in 96 well Nunc Maxisorp
TM plates 
(Fisher scientific, Leicester, UK). All assays were performed at room temperature 
and all standards and samples were run in duplicate. Any samples outside the 
detection range of the assay were repeated after appropriate dilution. (BD 
Pharmingen, Oxford, UK). The ELISA was carried out as per the manufacturer’s 
recommended assay procedure. 
The assay procedure remained the same for both the cytokines. All chemicals used in 
the assay were obtained from BD Pharmingen, Oxford, UK.  In brief the microwells 
were coated with 100µl per well of capture antibody diluted in coating buffer (0.1 M 
Sodium Carbonate, pH 9.5). The plates were sealed and incubated overnight at 4
ºC. 
The wells were aspirated and washed 3 times with ≥ 300 µl/well of wash buffer (PBS 
with 0.05% Tween-20). Any residual buffer was removed by inverting the plate on to 
a blotting paper after the last wash. The plates were then blocked with ≥ 200 µl/well 
Assay diluent (PBS with 10% Fetal bovine serum, pH 7.0) and incubated at room   100
temperature for 1 hour. The wells were then washed and aspirated 3 times with wash 
buffer as before. Standards and samples were then prepared in Assay Diluent and 
100 µl/well of each standard, sample and control (Assay Diluent only) were pipetted 
into appropriate wells and incubated at room temperature for 2 hours after sealing the 
plate. The wells were then aspirated and washed with wash buffer as before, but the 
wash was repeated 5 times. 100 µl/well of Working Detector (Detection Antibody + 
Avidin-horseradish peroxidase conjugate) was added to each well. The plate was 
then sealed and incubated at room temperature for 1 hour. The wells were then 
washed and aspirated with wash buffer as before but the wash was repeated 7 times 
and each well was soaked for 30seconds for each wash. 100 µl/well of substrate 
solution (Tetramethylbenzidine and hydrogen peroxide) was added to each well and 
the plate was incubated at room temperature for 30 minutes in the dark without the 
plate sealer. 50 µl/well of  Stop Solution ( 1M H3PO4 or 2 N H2SO4 ) was added and 
absorbance was read at 450nm within 30 minutes and a wavelength correction by 
subtracting absorbance at 570nm was applied. The mean absorbance for each set of 
duplicate standards, controls and samples were calculated. A standard curve was then 
plotted with TNF-α / Il-8 concentration on the X-axis and absorbance on the Y-axis 
and the indivdual sample cytokine concentration was then determined. 
4.8: Liver transaminases 
Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) were measured 
in serum. Blood samples were centrifuged at 2000g for 10 min at room temperature. 
Serum was separated from the samples and stored at -20
oC until assayed. 
Measurements were made using an automated clinical chemistry analyzer (Hitachi
® 
747, Roche Diagnostics, Lewes, UK).   101
4.9: Data collection and statistical analysis 
Data from the pulse oximeter and blood pressure monitor was collected continuously 
on a laptop computer. The data was averaged for one minute before the induction of 
Ischaemia (baseline), at the end of Ischaemia and 1, 2, 4 & 6 post reperfusion. Serum 
samples were taken at 1, 2, 4 and 6 hours following reperfusion for TNFα, IL-8, ALT 
and AST assay.Values are expressed as mean ± SD.  For statistical analysis, 
Student’s t-test for paired samples and one-way analysis of variance (ANOVA) with 
Bonferroni adjustment for multiple comparisons was used. P < 0.05 was considered 
statistically significant. All statistical analysis was performed on Graph pad Prism 
version 4. 
 
4.10: Bile flow and Proton nuclear magnetic resonance 
1HNMR spectroscopy 
Bile samples were taken at baseline and each hour thereafter and stored at -80°C. 
Bile volume was expressed as µL/min/100g of liver weight. 
1HNMR analysis was 
performed on an 11.7 Tesla (500 MHz for protons) spectrometer (Varian Unity +; 
Varian, Palo Alto, CA, USA) at 25
oC. Bile was thawed at room temperature and 
placed in 5mm NMR tube. For a field/frequency, lock a coaxial capillary insert was 
used (Wilmad, Buena, NJ, USA). This capillary insert was filled with a deuterium 
oxide solution of sodium [
2d4] trimethysilylpropionate (TSP) that acted both as a 
chemical shift reference and quantification standard. This capillary was calibrated by 
using a series of known concentration solutions of deoxycholate and a calibration 
curve was obtained. This was then used for quantification of bile components, which 
enabled an accurate comparison bile levels between the groups. One dimensional 
NMR spectra were obtained at 500 MHz with a sweep width of 6 kHz and 32 k data 
points in 64 scans were collected in both normal and spin echo mode. Presaturation 
of bile was carried out to attenuate the intensity of water signal. The spectra were 
analysed using software from MestRe-C version 3.1.1 (Universidade de Santiage de   102
Compostela, Spain). All spectra were integrated using a fixed range for each peak 
and published peak assignments(268).  
Results are presented as mean ± standard deviation (SD). The statistical analysis was 
performed using a one-way analysis of variance (ANOVA) with multiple 
comparisons adjusted for by the Bonferroni test. Statistics were calculated using 
commercially available software ( SPSS release 11.0.0; SPSS Inc., Chicago, IL, 
USA). P<0.05 was considered statistically significant. 
4.11 Summary of the methods used  
This section of the thesis focuses on the effect of glycine on liver IRI in a well 
established intermediate animal model of partial lobar liver IRI. A sham operated 
group was specifically used in order to evaluate the effects of prolonged surgery and 
anaesthesia as is commonly encountered in the clinical setting of liver resections or 
liver transplantation surgery. The employment of a tracheostomy permitted a stable 
haemodynamic  model which allowed assessment for this prolonged 
duration(134;145). A time period of 6 hours of reperfusion was chosen in order to 
allow assessment of changes not only in the early phase but also during the 
beginning of the late phase of IRI(184). Systemic haemodynamic parameters (BP 
and Heart rate) were monitored by arterial line and temperature with a PR probe. 
The intermediate size of the model allowed for the simultaneous placement of both 
the LDF and NIRS probes and frequent sampling of blood to evaluate plasma levels 
of the cytokines studied without haeomodynamic compromise(145). 
Laser Doppler Flow was used to study changes in hepatic microcirculation, while 
changes in the portal blood flow were monitored with ultrasonic transit time 
flowmetry probes. The NIRS was utilised to study changes in tissue CytOx, which 
reflects intracellular tissue oxygenation and mitochondrial activity.   103
Bile flow was monitored and bile composition analysed by 
1HNMR spectroscopy. 
This is the first time 
1HNMR spectroscopy has been used to study the effect of 
glycine on bile composition in a invivo model of liver IRI. 
Finally the two key cytokines (TNF-α and IL-8) involved in liver IRI were analysed 
by ELISA while liver enzymes (ALT & AST) were analysed by a commercially 
available clinical chemistry autoanalyser.     
The next chapter summarizes the experimental findings and effects of intravenous 
glycine on hepatic haemodynamics, hepatic microcirculation, and portal blood flow 
following liver IRI.   104
 
 
 
Chapter 5 
The role of glycine in liver ischaemia reperfusion inury and  
its effect on hepatic microcirculation, tissue oxygenation and  
Portal blood flow   105
5.1 Introduction: 
 
The effects of intravenous glycine on hepatic haemodynamics, hepatic 
microcirculation and portal blood flow following liver IRI are studied in the invivo 
model of partial lobar liver IRI as described in the methods chapter sections 4.1 – 
4.5. 
The effects of liver IRI on hepatic microcirculation are reviewed in chapter 1. In 
brief the pathophysiological changes of liver IRI obstruct hepatic sinusoidal blood 
flow leading to hepatic hypoperfusion (194). The severity of the sinusoidal perfusion 
failure is dependent on the ischaemia time (187) leading to primary sinusoidal 
perfusion failure ‘’no reflow’’(147) and ‘’reflow paradox’’ (292;320). 
Sinusoidal impairment leads to reduced hepatic tissue oxygenation and 
hepatocellular integrity, culminating in deterioration of parenchymal function (340). 
Thus impairment of microcirculation and sinusoidal perfusion augments the 
reperfusion injury by increasing the hypoxic conditions during reperfusion (402). 
Glycine is a nonessential amino acid and an inhibitory neurotransmitter in the central 
nervous system. It has been shown to be protective against hypoxia, Ischaemia and 
ATP depletion induced cell death in various experimental models 
(210;258;420;432;440) . There are several experimental studies which have  shown 
beneficial effects of glycine on warm liver I/R injury (14;24;258;327;358;440) . The 
aim of the present study was to investigate the effect of glycine on cellular energy 
production by studying mitochondrial activity as expressed by redox state of 
cytochrome oxidase and the effect of glycine on hepatic microcirculation.   106
5.2 Animal model and methods 
The animal model and groups including the various methods used in this study have 
been described in detail in chapter 4 section 4.1- 4.5. 
5.2.1: Animal model 
Three groups of animals were used (n=6) in each group. Sham group of animals 
underwent anaesthesia and laparotomy but no ischaemia or reperfusion was induced. 
The Control group had 1 hour of ischaemia and 6 hours of reperfusion and the 
Glycine group, which received an additional 300mosm of glycine given 
intravenously at a dose of 5ml/kg body weight prior to induction of ischaemia by 
slow intravenous infusion over 15 minutes. An equivalent volume of normal saline 
was injected in the control group of animals. 
Hepatic microcirculation was continuously measured via a probe placed on a fixed 
site on the median lobe of the liver and held in place by a retort holder during 
ischaemia and reperfusion period. Hepatic tissue oxygenation was continuously 
measured via optodes placed on the surface of the left liver lobe during ischaemia 
and reperfusion period. The portal vein flow was monitored continuously using a 
3mm transonic Doppler flow probe (Transonic Medical Flowmeter system, HT207; 
Transonic Medical System, Ithaca, New York, USA). 
5.2.2:Data collection and statistical analysis 
Data from the pulse oximeter and blood pressure monitor was collected continuously 
on a laptop computer. The data was averaged for one minute before the induction of 
Ischaemia (baseline), at the end of Ischaemia and 1, 2, 4 & 6 hours post reperfusion.  
A laptop computer connected to the NIRS spectrometer continuously collected the 
NIRS data.A software program called ONMAIN
® (Hamamatsu Photonics K.K, 
Hamamatsu , Japan) was used to convert these data into changes in concentration of 
Cyt Ox (µmol/l) using the previously defined algorithm in the NIRO 500. This data   107
was then transferred to excel
® data sheets (Microsoft Corporation, Seattle, USA) for 
analysis. The data was collected at the relevant time points as mean of 2 minute 
measurements and calculated in regard to the baseline value (zero set at start of 
experiment).   
Data from the continuous measurement of portal blood flow by the ultrasonic 
flowmeter were collected via the NIRS program. After conversion of the NIRS data 
to excel sheets, the ultrasonic flowmeter data at the relevant points was calculated as 
a mean of 1-minute data. 
Data from the LDF was recorded and collected continuously.The LDF data was 
collected   before the application of ischaemia as baseline and at end of 1 hour of 
ischaemia, and at 1,2,4 and 6 hours after onset of reperfusion as a mean of 2 minute 
data. 
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5.3: Results 
5.3.1: Systemic Hemodynamic parameters 
Heart rate was stable in all 3 groups throughout the entire duration of the 
experimental protocol with no significant differences between the groups.In the sham 
group, the mean arterial blood pressure remained stable throughout the duration of 
the experiment. In the control and glycine groups the mean arterial blood pressure 
fell in the first hour of reperfusion and this was statistically significant between the 
sham & control and control & glycine (p<0.05) groups, while there was no difference 
between the sham and glycine groups at this time point. During the second and fourth 
hours of reperfusion there was statistically significant drop in mean arterial blood 
pressure in the control group as compared to sham while there was no difference 
observed between the control and glycine groups. However, it was only in the sixth 
hour that the mean arterial blood pressure was significantly better in the sham and 
glycine groups as compared to control (fig 5.1 and fig 5.2). 
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Figure 5.1: Heart rate 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.2: Mean arterial blood pressure 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* = p<0.05; Glycine+I/R v/s I/R alone 
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5.3.2: Hepatic Portal vein blood flow 
The baseline portal blood flow was higher in the glycine group and this was 
statistically significant as compared to the control group but not as compared to 
sham. During Ischaemia portal blood flow was reduced in both the control and 
glycine groups (p<0.05).  The reduction started one min after the induction of 
Ischaemia and was maximal by 15 min. During the reperfusion period, the portal 
blood flow improved in the glycine group and was statistically significant at 1, 2, 4, 
and 6 hours of reperfusion as compared to the control group. There was no 
statistically significant difference observed in the portal blood flow between sham & 
control and sham & glycine groups, except in the sham v/s glycine group at 6 hours 
of reperfusion wherein the portal blood flow was significantly better in the glycine 
group as compared to the sham group (fig 5.3). 
 
Figure 5.3: Portal blood flow 
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5.3.3: Hepatic microcirculation by LDF 
There was no significant difference in the hepatic microcirculation over eight hours 
of sham operation. Following I/R the flow in the microcirculation was reduced in the 
Control group as compared to sham operated animals at 2, 4, and 6 hours of 
reperfusion and this was statistically significant (fig 5.4). In the glycine, treated 
group there was a significant improvement in the hepatic microcirculation as 
compared to the control group at 2, 4, and 6 hours of reperfusion. 
 
 
Figure 5.4: Hepatic microcirculation (LDF) 
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5.3.4 Hepatic tissue oxygenation by NIRS 
There was no difference in the baseline CytOx levels between the three groups. 
During Ischaemia, there was a significant reduction in CytOx, which was maximal at 
15-20 minutes after induction of Ischaemia. After reperfusion, in the control group 
CytOx levels returned towards baseline values during the first hour of reperfusion, 
but subsequently reduced. In the glycine group, a similar trend was observed 
immediately upon reperfusion, however the CytOx levels returned towards values 
observed in sham operated animals by the fourth hour of reperfusion and then 
decreased towards the end of the sixth hour. The improvement in CytOx levels was 
statistically significant at the fourth and sixth hour of reperfusion as compared to the 
control group (P<0.001) (fig 5.5). 
 
Figure 5.5: Hepatic tissue oxygenation (CytOx) 
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5.4 Discussion 
In this study a rabbit lobar warm IRI model was used with continuous monitoring of 
systemic and hepatic haemodynamic parameters along with monitoring of hepatic 
microcirculation. A sham operated group was specifically used in order to evaluate 
the effects of prolonged surgery and anaesthesia as is commonly encountered in the 
clinical setting of liver resections or liver transplantation surgery. The employment 
of a tracheostomy permitted a stable haemodynamic  model which allowed 
assessment for this prolonged duration (134;145). A time period of 6 hours of 
reperfusion was chosen in order to allow assessment of changes not only in the early 
phase but also during the beginning of the late phase of IRI (184). 
In the sham operated animals the systemic and local haemodynamic parameters 
remained stable throughout the duration of the operation. However gradual 
deterioration in microcirculation and levels of Cytox were noted although this was 
not statistically significant. This could be attributed to the prolonged anaesthesia and 
surgical procedure. The portal blood flow remained stable during the procedure.  
There was a significant drop in portal blood flow during induction of ischaemia 
which was observed in the Control group (v/s Sham), which may be due to occlusion 
of the portal pedicle of the median and the left lobe. A similar drop was observed in 
the glycine treated group but it was significantly less as compared to control. Also 
the portal blood flow was observed to be significantly better than control group at all 
time points throughout the operation in the Glycine group. This could be due to 
splanchnic vasodilatation induced by the bolus dose of glycine given at the start of 
the operation. A similar effect was not observed either in the sham or control group 
animals even though they received a similar volume of normal saline at the start of 
the operation. This splanchnic vasodilatation has not been previously reported.   114
Changes in CytOx levels are indicative of the level of intracellular oxygenation and 
mitochondrial activity(101;145).In the present study, in the control group, CytOx 
levels fell significantly during the Ischaemia period and then started to improve 
during the first hour of reperfusion. Following this initial partial recovery, there was 
a gradual decrease in CytOx levels, which by the sixth hour were similar to levels 
during Ischaemia. This fall in CytOx levels after initial partial recovery could be 
attributed to reperfusion injury and its associated changes. Interestingly, in the 
glycine treated group, a similar trend was observed and the fall in CytOx was 
significantly less (v/s Control) by the end of fourth hour of reperfusion when the 
levels returned to those observed in the sham operated group and this was maintained 
up to the sixth hour of reperfusion. Thus, glycine not only protects during the early 
phase but also significantly decreases the extent of cellular injury in the early part of 
the late phase of hepatic IRI. 
Similar changes were observed in hepatic microcirculation, which was reflected by 
the changes in LDF. In fact, significant recovery of microcirculation was observed at 
two hours of reperfusion and which was maintained up to six hours of reperfusion. 
Thus, recovery of microcirculatory changes prior to recovery of CytOx would 
suggest that recovery of microcirculation is paramount prior to recovery of cellular 
injury. The LDF data and the CytOx data suggests that inhibiting KC activation 
during the early phase of IRI not only ameliorates the early phase but also improves 
the early part of the late phase of IRI. 
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5.5: Conclusion 
In conclusion in the experimental model used in this study, intravenous glycine 
ameliorated the haemodynamic alterations in both the early and beginning of the late 
phase of hepatic IRI. The effect on portal blood flow has not been reported before. 
However the microcirculatory changes are a part of the initial pathophysiologic 
changes in liver IRI as reviewed in Chapter 1.The experimental work in the next 
chapter assesses the effect of glycine on two other key pathophysiologic 
phenomenon (cytokine expression and hepatic enzymes) which reflect and augment 
the changes in the microcirculation.   116
 
 
 
Chapter 6 
The Role of glycine in liver ischaemia reperfusion injury and its 
effect on cytokine expression and liver function 
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6.1: Introduction 
In this chapter the effect of  a single dose of intravenous glycine on cytokine 
expression and liver function following warm liver IRI is studied  in a invivo model 
of partial lobar liver IRI as described in the methods chapter sections 4.1 and 4.6- 4.8 
The role of cytokines in liver IRI has been reviewed in chapter 1. In brief.Hepatic I/R 
injury is initiated by activation of KC in the liver during Ischaemia (72;192;194) . 
However it is the cytokine release by these activated KC which plays a pivotal role in 
the inflammatory response during hepatic IRI(72;192;251) .Cytokines play an 
important role in liver IRI, both by initiating and sustaining the inflammatory 
response as well as modulating it’s severity (351;388). Cytokines due to their ability 
to act in an autocrine, paracrine, and humoral manner not only initiates and maintains 
the inflammatory response (351), but also induce production of other inflammatory 
mediators like other cytokines , chemokines and eicosanoids(71;351)  
Tumour necrosis factor alpha (TNF) and interleukin-1 (IL1) are the key cytokines 
which are produced by activated KC and are most commonly implicated in hepatic 
IRI (71;369). These two cytokines in turn induce IL-8 synthesis, which initiates the 
late phase of liver IRI (71;388).  
Inflammatory cytokines such as TNF-α are associated with the induction of cellular 
adhesion molecules and hepatic microcirculatory impairment based on neutrophil-
vascular endothelial cell interaction (71). Members of the chemokine family such as 
IL-8, CINC, MIP-2, and MCP-1 are involved in neutrophil infiltration in the liver 
and remote organs further accentuating liver injury (314;351).  
Thus suppression of these inflammatory mediators may not only reduce liver injury 
inherent to IRI but also ameliorate remote organ injury. Serum levels of liver 
enzymes viz AST & ALT  reflects hepatocytes integrity/damage since they are   118
cytosolic enzymes and hence  released in event of injury/damage to the 
hepatocytes(134;145;198). 
Glycine a non essential amino acid and inhibitory neurotransmitter has been shown 
to inhibit KC activity when administered either orally or intravenously 
(179;210;326;329;432). There are several experimental studies which have  shown 
beneficial effects of glycine on warm liver I/R injury(14;258;327;358;440). 
The aim of the present study was to investigate the effect of glycine on cytokine 
production (TNFa and IL-8) and liver enzymes (AST & ALT).   119
6.2: Animal model and methods:  
The animal model and groups including the various methods used in this study have 
been described in detail in chapter 4 sections 4.1 and 4.6 - 4.9. 
6.2.1: Animal model 
In brief, this study was conducted under a license granted by the home office in 
accordance with the Animals (Scientific Procedures) Act 1986. New Zealand white 
rabbits (3.2 ± 0.4Kg, n=18) were used for the experiments.  
  Ear marginal vein was cannulated with radio opaque catheter 20 gauge for 
administration of fluids, anaesthetics, and blood sampling. Ear marginal artery was 
cannulated with a 20-gauge radio opaque catheter and connected to a pressure 
transducer for monitoring the mean arterial blood pressure. Lobar liver IRI was 
induced as per the experimental protocol described previously.Three groups of 
animals were used (n=6) in each group. Sham group of animals underwent 
anaesthesia and laparotomy but no ischaemia or reperfusion was induced. The 
Control group had 1 hour of ischaemia and 6 hours of reperfusion and the Glycine 
group, which received an additional 300mosm of glycine given intravenously at a 
dose of 5ml/kg body weight prior to induction of ischaemia by slow intravenous 
infusion over 15 minutes. An equivalent volume of normal saline was injected in the 
control group of animals. Blood samples were collected at 1, 2, 4 and 6 hours 
following reperfusion for assessment of serum cytokines (ELISA) and transaminases. 
6.2.2: TNF-α ELISA  
For the TNF-α ELISA (BD Pharmingen, Oxford, UK) the primary antibody (capture 
antibody) was a purified goat anti-rabbit TNF-α and the secondary antibody 
(detection antibody) a biotinylated goat anti-rabbit TNF-α antibody. Both the 
antibodies were titrated to determine optimal concentrations for ELISA capture and   120
detection. To obtain linear standard curves doubling dilutions of recombinant rabbit 
TNF-α protein ranging from 10,000 – 80 pg/ml were included in each ELISA plate. 
6.2.3: IL-8 ELISA  
An OptEIA
TM Rabbit IL-8 set (BD Pharmingen, Oxford, UK) was used. The set 
contained an anti-rabbit IL-8 antibody for capture and a biotinylated anti-rabbit IL-8 
antibody as a detection antibody. To obtain linear standard curves doubling dilutions 
of recombinant rabbit IL-8 ranging from 200-0 pg/ml were used. All ELISA’s were 
performed in 96 well Nunc Maxisorp
TM plates (Fisher scientific, Leicester, UK). All 
assays were performed at room temperature and all standards and samples were run 
in duplicate. Any samples outside the detection range of the assay were repeated 
after appropriate dilution. (BD Pharmingen, Oxford, UK). The ELISA was carried 
out as per the manufacturer’s recommended assay procedure. The assay procedure 
remained the same for both the cytokines. All chemicals used in the assay were 
obtained from BD Pharmingen, Oxford, UK.   
Alanine aminotransferase (ALT), Aspartate aminotransferase (AST) were measured 
in serum. Blood samples were centrifuged at 2000g for 10 min at room temperature. 
Serum was separated from the samples and stored at -20
oC until assayed. 
Measurements were made using an automated clinical chemistry analyzer (Hitachi
® 
747, Roche Diagnostics, Lewes, UK). 
6.2.4 Data collection and statistical analysis 
 
Data from the pulse oximeter and blood pressure monitor was collected continuously 
on a laptop computer. The data was averaged for one minute before the induction of 
Ischaemia (baseline), at the end of Ischaemia and 1, 2, 4 & 6 hours post reperfusion.  121
Serum samples were taken at 1, 2, 4 and 6 hours following reperfusion for TNFα, IL-
8, ALT and AST assay. Values are expressed as mean ± SD.  For statistical analysis, 
Student’s t-test for paired samples and one-way analysis of variance (ANOVA) with 
Bonferroni adjustment for multiple comparisons was used. P < 0.05 was considered 
statistically significant. All statistical analyses were performed on Graph pad Prism 
version 4.   122
6.3 Results 
6.3.1 Systemic haemodynamic parameters 
The results for systemic haemodynamics parameters are as described previously in 
chapter 5 section 5.3.1 and figures 5.1 and 5.2. 
 
 
6.3.2 Serum TNF- α levels  
There was no significant change in serum TNF-α levels over the duration of the 
experiment in the sham group. IR alone was associated with significantly elevated 
TNF-α levels. glycine administration produced a significant reduction in TNF-α 
levels following I/R at 1, 2 and 4 hours post reperfusion.(fig 6.1) 
 
Figure 6.1: Serum TNF-α 
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6.3.3: Serum IL-8  
Serum IL-8 levels gradually reduced in the sham operated group over the course of 
the experiment. IR alone significantly increased serum IL-8 levels over the entire 
reperfusion period as compared to sham operated group. In the glycine treated group 
a significant reduction in serum IL-8 levels was observed over the entire reperfusion 
period.( fig 6.2)  
 
Figure 6.2: Serum IL-8 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* = p<0.05; Glycine+I/R v/s I/R alone 
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6.3.4 Serum AST and ALT  
Serum AST and ALT levels steadily increased in the sham operated animals over the 
course of the experiment. IR alone significantly increased the transaminase levels as 
compared to sham operated group. In the Glycine treated group, a significant 
reduction in serum transaminases was observed throughout the entire reperfusion 
period. (fig 6.3 and 6.4)  
 
 
Figure 6.3: Serum aspartate transaminase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* = p<0.05; Glycine+I/R v/s I/R alone 
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Figure 6.4: Serum alanine transaminase 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* = p<0.05; Glycine+I/R v/s I/R alone 
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6.4 : Discussion 
Glycine is a nonessential amino acid and an inhibitory neurotransmitter, which has 
been shown to modulate KC activity. Oral glycine has been shown to reduce warm 
IRI in different organs in a variety of experimental animal models 
(179;256;418;432;440).  
In this study an established rabbit lobar warm IRI model (134;145) was used with a 
sham group to allow the effects of prolonged surgery and anaesthesia to be 
evaluated. The employment of a tracheostomy permitted a stable haemodynamic 
model which allowed assessment under prolonged anaesthesia(134;145). A time 
period of 6 hours of reperfusion was chosen in order to allow assessment of changes 
not only in the early phase but also during the beginning of the late phase of 
IRI(114;187). In the sham operated animals the systemic haemodynamic parameters 
remained stable throughout the duration of the operation.  
TNF-α is one of the main cytokines released by KC and has a key role  in early liver 
IRI (72;184;405). Glycine reduced the cytokine release following I/R suggesting 
direct KC inhibition as previously documented(210). IL-8 is another cytokine 
released by activated neutrophils and KC which is responsible for neutrophil 
activation and recruitment thereby promoting the second more sustained phase of 
cellular injury following liver IRI (114;187;191;351). In this study preconditioning 
with intravenous glycine prior to Ischaemia significantly reduced IL-8 levels, an 
effect of glycine not previously reported.  
Serum AST and ALT are cytosolic enzymes which are markers of the severity of 
hepatocellular injury (134;145;160;291;292)
 . In this study the significant reduction 
in the serum levels of these enzymes in the glycine treated group confirms the 
cytoprotective effect of glycine in liver IRI.   127
6.5 : Conclusion 
In conclusion, a single dose of intravenous glycine improved the early phase of 
hepatic IRI in this experimental model. There was sustained amelioration of two key 
cytokines involved in the early pathophysiology of liver IRI. The significant 
improvement in liver enzymes would be suggestive of hepatocellular protection 
conferred by the single intravenous dose of glycine.  
Liver IRI significantly impacts on bile flow and bile composition. In fact bile flow has 
been used as a marker of liver function and recovery following ischaemia in 
experimental studies(31;142) and clinical liver transplantation(122;233) and 
persistently low bile output is considered to be a sign of primary non function(233). In 
the next chapter the next set of experiments elucidates the effect of glycine on bile flow 
and bile composition in the same animal model.   128
 
 
 
Chapter 7 
Bile flow and bile (
1HNMR) spectroscopy in liver ischaemia 
reperfusion injury and the effect of glycine 
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7.1: Introduction 
Bile formation is an active secretory process both of individual hepatocytes and of 
integrated bilary transport mechanisms (31) that is used as an indicator of liver function 
and recovery following ischaemia in experimental studies (31;142) and clinical liver 
transplantation (122;233).  
IR injury has been shown to manifest by poor bile flow in vitro(167) and in vivo 
(31;142) and reduced bile acid secretion. However, gradual recovery occurs in 
reversibly damaged organs while persistently low bile output is considered to be a 
sign of primary non function (233). Little is known, however, about changes in bile 
composition during liver IRI and infact very little is known about the effect of 
therapeutic strategies to ameliorate IRI on bile composition, which will be the 
primary focus of this study. Bile salts are a major component of bile and significantly 
influence bile flow and secretion of biliary lipids such as phosphatidylcholine (PC, 
also known as lecithin) and cholesterol (107). 
Bile salts are transported across the canalicular membrane in a primary active ATP 
dependent fashion (135;366) which is mediated by the bile salt export pump (BSEP) 
(287). BSEP is a genuine ATP-binding cassette (ABC) transporter according to the 
classic paradigm of 12 transmembrane spanning domains and ATP-binding folds, 
similar to ABC transporters expressed in many tissues and involved in active 
outward transport of molecules across the plasma membrane (107). 
In recent years, high resolution proton nuclear magnetic resonance (
1HNMR) 
spectroscopy has been established as a powerful technique to explore the 
biochemical composition of biological fluids such as plasma, bile, seminal and 
synovial fluids, in various pathological conditions(356). This technique is robust, 
rapid, noninvasive and can detect metabolites present at millimolar concentrations 
and can be applied to detect unexpected compounds in biological fluids (141).  130
In bile, it has been used to confirm the hydrophobic association in micelles of 
conjugated bile acids and biliary lipids (355) and also to assess biliary lipid dynamics 
and the structure of micelle formation (362). It has also been used to assess the 
effects of cholesterol on the fluidity of human gallbladder bile (108;343). It has been 
also used to quantitatively determine the amount of total and taurine conjugated bile 
acids in bile obtained from rats (182) and to identify the lipid content of cellular or 
mitochondrial plasma membranes (304). 
1H NMR has also been used to assess 
hepatic glutamine metabolism (399), hepatic energetic status after warm ischaemia 
(323) and to study the effect of IR on liver cell membranes (165).  In liver 
transplantation, an initial study of 
1HNMR analysis applied to T-tube bile after liver 
transplantation has been reported by Powell et al in 1990, suggesting that this 
technique might help to distinguish ischaemia from rejection post-transplant by 
detecting large resonance peaks for lactate and acetate (306).  More recently there 
has been growing interest in attempting to predict graft function by analysing bile 
production immediately after transplantation (268) 
Therefore, the aim of this study was to investigate the effect of liver warm IRI on 
bile flow and composition and the effect of glycine a KC modulant on bile 
composition and flow in an invivo established animal model of partial lobar liver 
IRI. We propose to study bile flow and bile acid levels as surrogate markers of 
synthetic function. To assess impact of IRI on hepatocellular injury we plan to assess 
levels of lactate and phosphatidylcholine (PC) in bile.Bilary acetate, pyruvate, 
glucose, and acetoacetate will serve as metabolic indicators of hepatocellular 
function. 
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7.2: Animal model and methods:  
 
The animal model and groups including the various methods used in this study have 
been described in detail in chapter 4 section 4.1, 4.2, and 4.10.  
 
7.2.1: Bile flow and proton nuclear magnetic resonance 
1H NMR spectroscopy  
The bile duct was cannulated with a polyethylene catheter (PE-50, 0.58mm inner 
diameter, Portex, Kent, UK) for continous measurement of bile flow. Bile samples 
were taken at baseline and each hour thereafter and stored at -80°C. Bile volume was 
expressed as µL/min/100g of liver weight. 
1H NMR analysis was performed on an 
11.7 Tesla (500 MHz for protons) spectrometer (Varian Unity +; Varian, Palo Alto, 
CA, USA) at 25
oC. Bile was thawed at room temperature and placed in 5mm NMR 
tube. For a field/frequency lock a coaxial capillary insert was used (Wilmad, Buena, 
NJ, USA). This capillary insert was filled with a deuterium oxide solution of sodium 
[
2d4] - trimethysilylpropionate (TSP) that acted both as a chemical shift reference and 
quantification standard. This capillary was calibrated by using a series of known 
concentration solutions of deoxycholate and a calibration curve was obtained. This 
was then used for quantification of bile components, which enabled an accurate 
comparison of bile levels between the groups. One dimensional NMR spectra were 
obtained at 500 MHz with a sweep width of 6 kHz and 32 k data points in 64 scans 
were collected in both normal and spin echo mode. Pre saturation of bile was carried 
out to attenuate the intensity of water signal. The spectra were analysed using 
software from MestRe-C version 3.1.1 (Universidade de Santiage de Compostela, 
Spain).The various markers studied included synthetic functional markers (bile flow 
and bile acid synthesis), injury markers (lactate and PC levels) and metabolic 
indicators (acetate, pyruvate, glucose and acetoacetate). All spectra were integrated   132
using a fixed range for each peak and published peak assignments (268). Baseline 
control bile spectra are shown in fig 7.1 
 
Figure 7.1: 
1HNMR spectrum of baseline control bile 
 
 
Key: TSP=sodium trimethylsilyl-[
2H4] propionate standard, BA=bile acid, Lact=lactate, Ac=acetate, 
Acc=Acetoacetate, Py=pyruvate, PC=phosphatidylcholine head group, H2O=water, Gl=glucose. 
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7.2.2: Data collection and statistical analysis 
Results are presented as mean ± standard deviation (SD). The statistical analysis was 
performed using a one-way analysis of variance (ANOVA) with multiple 
comparisons adjusted for by the Bonferroni test. Statistics were calculated using 
commercially available software ( SPSS release 11.0.0; SPSS Inc., Chicago, IL, 
USA). P<0.05 was considered statistically significant. 
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7.3: Results 
7.3.1: Systemic haemodynamic parameters 
The results for systemic haemodynamics parameters are as described previously in 
chapter 5, section 5.3.1 and figures 5.1 and 5.2. 
7.3.2: Bile flow  
Baseline bile flow was similar in all groups (150μl/min/100gm wet liver weight). 
Bile flow remained stable in the sham group throughout the duration of the 
experiment. Bile flow was reduced with ischaemia and improved during the 
reperfusion period. The glycine IR group showed a significantly increased bile flow 
throughout the reperfusion period as compared with IR alone group (Fig 7.2). 
 
Figure 7.2: Bile flow 
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7.3.3: Bile Acids:  
  The results of the integration of the area under curve for the peaks assigned to 
conjugated bile acids in the sham group bile were relatively unchanged throughout 
the experiment at 4.91±0.95 mol/L (fig. 7.3). Control group bile acid levels tended 
to be higher than shams throughout the experiment (P=0.002 when total group means 
were compared), however, they did not reach statistical significance when compared 
at each time point. In  the glycine group bile acid levels rose significantly following 
Ischaemia to peak during the 1
st hr of reperfusion, where they were significantly 
higher than both shams (P<0.001) and controls (P=0.001). They remained 
significantly elevated, compared to both shams and controls, during the 2
nd and 4
th hr 
of reperfusion (P<0.05). 
 
Figure 7.3: Bile acids levels following warm liver I/R and glycine 
 
 
Bile acid levels were calculated by integration of peaks at 0.61-0.73 ppm and 
expressed as mol/L;   * = p<0.05; Glycine+I/R v/s I/R alone   136
7.3.4: Bile Phosphatidylcholine 
Integration of peaks corresponding to phosphatidylcholine (PC) revealed no 
difference between glycine and sham groups throughout the experiment (fig.7.4). PC 
levels in the control group, however, increased gradually till the 2
nd and 4
th hr of 
reperfusion where they were significantly higher than controls and shams (P<0.05).  
 
Figure 7.4: Bile phosphatidylcholine levels following 
warm liver I/R and glycine 
 
 
 
Phosphatidylcholine levels were calculated by integration of peaks at 3.2 ppm 
and expressed as mol/L,   * = p<0.05; Glycine+I/R v/s I/R alone 
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7.3.5: Bile Lactate  
Similarly, there was no statistical difference in bile lactate levels between glycine 
and sham groups during the procedure (fig. 7.5); however, in the control group they 
increased, following reperfusion, to peak significantly at 4 hrs (P<0.001 vs. controls). 
 
 
Figure 7.5: Bile lactate levels following warm liver I/R and glycine 
 
 
 
 
 
Lactate levels were calculated by integration of peaks at 1.33 ppm and 
expressed as mol/L; * = p<0.05; Glycine+I/R v/s I/R alone   138
7.3.6 Bile acetate 
There was no statistical difference in bile acetate concentration between sham and 
glycine groups throughout the experiment (fig. 7.6). Acetate levels for all groups fell 
dramatically at 1 hr reperfusion. The sham and glycine groups regained their baseline 
values by the end of reperfusion and were not statistically different, while in the 
control group they remained depressed compared to glycine (P<0.01).  
 
Figure 7.6: Bile acetate levels following warm liver I/R and glycine 
 
 
 
Acetate levels were calculated by integration of peaks at 1.9 ppm and expressed 
as mol/L,      * = p<0.05; Glycine+I/R v/s I/R alone    139
7.3.7 Bile Pyruvate  
Bile levels of pyruvate in control and sham groups were similar throughout the 
experiment (fig. 7.7). In the glycine group, however, they were significantly elevated 
during the 2
nd and 4
th hr of reperfusion compared to both sham and control groups 
(P<0.05). 
 
Figure 7.7: Bile pyruvate levels following warm liver I/R and glycine 
 
 
 
Pyruvate levels were calculated by integration of peaks at 2.3 ppm and 
expressed as mol/L,     * = p<0.05; Glycine+I/R v/s I/R alone 
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7.3.8 Bile Glucose  
There was no statistical difference between bile -glucose levels in sham and control 
groups throughout the experiment (fig. 7.8). However, there was a significant rise in 
-glucose levels in the glycine group from the 1
st hr of reperfusion until the 4
th hr of 
reperfusion (P<0.05).  
 
Figure 7.8: Bile glucose levels following warm liver I/R and glycine 
 
 
 
Glucose levels were calculated by integration of peaks at 5.2 ppm and expressed 
as mol/L,     * = p<0.05; Glycine+I/R v/s I/R alone   141
7.3.9 Bile Acetoacetate  
Acetoacetate levels were not statistically different for sham and control groups 
during the experiment (fig. 7.9). The glycine group, however, was significantly 
elevated during the ischemic phase, 1
st, 4
th and 6
th hr of reperfusion when compared 
to both sham and control groups (P<0.05). 
 
Figure 7.9: Bile Acetoacetate levels follow warm liver I/R and glycine 
 
 
 
 
Acetoacetate levels were calculated by integration of peaks at 2.2 ppm and  
expressed as mol/L;    * = p<0.05; Glycine+I/R v/s I/R alone.   142
7.4: Discussion 
This is the first time that 
1HNMR analysis has been applied to study the effect of 
glycine on bile constituents in a controlled experimental model of liver I/R. The use 
of spin echo spectra in this study, allowed us to reduce the interference from broad 
lipid signals as well as identify and partially quantitate and compare bile constituents 
more accurately. Although the bile production in glycine and sham groups after 
reperfusion was similar, 
1H NMR spectroscopy of bile revealed differences in the 
levels of some bile constituents. 
In the present study, a rabbit lobar I/R model was used with reperfusion period of six 
hours(101), which permitted the analysis of bile constituents in both the early phase 
and the beginning of the late phase of I/R injury. The lobar I/R model was chosen, 
rather than one of total hepatic Ischaemia, as this avoids the production of acute 
portal hypertension and intestinal Ischaemia. In addition, lobar clamping avoids the 
complete occlusion of biliary drainage in the total hepatic Ischaemia model(196) and 
thus permitting the effects of I/R on biliary composition to be evaluated. 
Tracheostomy, ventilation and the use of Isoflurane, (which is metabolised in the 
lungs rather than in the liver) was useful in haemodynamically stabilising the model. 
and permitted bile constituents to be analysed into the late phase of I/R. This is 
supported by the relative stability of the sham findings. 
Bile flow was maintained throughout the procedure in the sham group, while it fell 
during the ischemic phase in the control and glycine I/R groups. This is consistent 
with the results of previous studies(31;101) . However, in the glycine group, bile 
flow on reperfusion recovered to become similar to sham within 2hrs of reperfusion, 
while in the control group remained depressed until the end of the experiment. 
Moreover, a rise in bile acid secretion was also noted on reperfusion, in the glycine 
group, compared to controls. This suggests an early recovery of metabolic activity in   143
the glycine-treated livers, which is supported by observations that total serum bile 
acids were found to be early markers of liver function in porcine(170) and 
canine(131) liver transplants.  The rise in bile acid observed during Ischaemia may 
be a result of the drop in bile flow.  
In this study, lactate levels were higher in the control group than in the sham and 
glycine groups. ATP degradation during ischaemia leads to the activation of 
glycolysis, resulting in the net formation of lactate(318;424). It has also been shown 
that glycogen concentration decreased as a function of the length of the ischemic 
period. This suggests that serum lactate may be a product of the 
glycolytic/gluconeogenic pathway, which was verified by showing glucose-6-
phosphate and fructose-6-phosphate to increase with I/R injury(301). However, the 
end product of this pathway is normally pyruvate, and lactate is not produced except 
during anaerobic situations(5).  It is interesting that this rise in lactate is observed at 
4hrs reperfusion, this corresponds to a large burst of neutrophil activity that 
constitutes the beginning of the late phase of Ischaemia-reperfusion injury(64). It has 
been observed that the injury produced during the initial part of the late phase is a 
more extensive hepatocellular injury in comparison to the early phase (64) (194)
. 
Moreover, elements of neutrophil sequestration, sinusoidal narrowing and 
vasoconstriction combine to form a “no-reflow paradox” where by hepatocytes are 
subjected to a further perfusion deficit and persistent ischaemia (64;194) . This may 
explain the observed peak in lactate at this late time point, especially since lactate 
levels have been shown to become elevated in bile even when they are not elevated 
in serum (283).  
In this study, PC was observed to be similar in sham and glycine groups, while it was 
raised in the control group during the 2
nd and 4
th hr of reperfusion. The main source 
of phosphatidylcholine in cells is in the plasma membrane, which suggests that the   144
post-reperfusion increase may be associated with an increase in cellular breakdown 
and membrane lipid peroxidation (368). Increased PC has also been observed in 
association with poor graft function (268).  
These results show an increase in post-reperfusion levels of biliary glucose and 
pyruvate on reperfusion in the glycine group compared to controls. This suggests an 
increased metabolic activity in the glycolytic/gluconeogenic pathway, which may be 
due to conserved cellular energetics. Hepatocytes are one of the few cells that can 
utilize fatty acids in the production of energy through the -oxidation helix, however, 
this reaction requires ATP at its initiation(5). Ischaemia–induced reduction of ATP 
may result in a decreased ability to utilize -oxidation causing acetate production to 
falter. The results show that glycine-treated livers possessed a greater ability to 
produce acetate than controls, which further suggests less injury to their metabolic 
energetics.  
After reduction of hepatic blood flow, the mitochondrial redox potential is reduced. 
Consequently, there is accelerated production of ketone bodies to compensate for 
inhibited glucose utilization. Ketone body production is an alternative pathway to 
supply ATP when there is inhibition of glucose oxidation and the Krebs cycle. 
Recently, higher acetoacetate perfusate levels have been demonstrated in isolated-
perfused rat livers preserved in University of Wisconsin versus Euro-Collins solution 
(141) which has been shown to correlate with NAD
+/NADH ratio in the hepatocyte 
mitochondria (421). The elevated levels of acetoacetate observed in this study, 
during ischaemia and reperfusion, suggests an early attempt by glycine-treated livers 
at utilising an alternative source of ATP. This finding further supports the suggestion 
of conserved cellular energetics in this group.   145
7.5: Conclusion 
Bile spectroscopy has demonstrated significant changes in bile composition during 
glycine administration. These changes are evident despite a constant post-reperfusion 
rate of bile flow. Glycine treatment was associated with increased synthetic 
functional markers (bile flow and bile acid synthesis), decreased injury markers 
(lactate and PC levels) and enhanced metabolic indicators (acetate, pyruvate, glucose 
and acetoacetate).  
The experimental data suggests that glycine ameliorates not only the haemodynamic 
changes and cytokine surge associated with IRI, but also significantly alters the bile 
composition and maintains bile flow during the early and the initial part of the late 
phase of hepatic IRI. The possible mechanism of action is maintenance of cellular 
energy production through amelioration of the systemic inflammatory response.  
However, the early pathophysiology of IRI would suggest that along with KC; ROS 
also play a key role in modulating the subsequent cellular events as reviewed in 
chapter 1. In order to ameliorate IRI secondary to ROS production,  we have 
assessed the effect of prophylactyically administered N-acetylcysteine, a antioxidant 
on liver IRI in patients undergoing elective liver resection within a pilot randomised 
controlled clinical trial in the next chapter. NAC has been widely used in clinical 
medicine however; it has never been used in this setting before.   
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Chapter 8 
Effect of N-acetylcysteine in hepatic resections:  
A pilot prospectively randomised double blind  
controlled clinical trial 
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8.1: Introduction  
Surgical resection is the gold standard treatment for patients with cancers of the liver, 
with acceptable morbidity (20%-30%) and mortality (0.6%-5%) (21;125;325). 
Minimizing blood loss during surgery improves clinical outcome (100;275;325). 
Total hepatic inflow occlusion (Pringle’s manoeuvre) can reduce operative blood 
loss, but leads to warm ischaemia-reperfusion (I/R) and pooling of portal blood. 
Warm I/R along with loss of liver volume leads to postoperative hepatocellular 
dysfunction (22;23;176). Warm I/R injury also occurs due to intraoperative 
mobilisation and compression of the liver due to retraction (327;331).Liver I/R injury 
is a significant cause of morbidity and mortality in these patients (92;250;427). 
Liver ischaemia causes depletion of ATP with subsequent impairment of energy 
dependant intracellular homeostatic mechanism (67;236;340;386). Reperfusion leads 
to microcirculatory disturbances due to cellular oedema, accumulation of toxic 
oxidative radicals, cytokines, and up regulation of vascular adhesion molecules 
accompanied with depletion of intracellular glutathione stores which  affects cellular 
metabolism and hepatocellular function (114;236;340;386).Reactive oxygen species 
(ROS) and adhesion molecules particularly ICAM-1 have a major role in the 
development of I/R injury (106;109;172;243;259). 
Antioxidant agents have been shown to improve haemodynamic variables and 
outcome in early liver failure of varied aetiology (57;144;146;163). N-
acetylcysteine(NAC) is one such agent which has been extensively used in clinical 
medicine for more than 25 years as a mucolytic agent, as a protective agent against 
the toxicity of drugs used for cancer and as a effective antidote in paracetamol 
poisoning (62;93;144;146).  The main mechanisms of action are: a) conversion to 
cysteine, b) replenishing the depleted intrahepatic glutathione stores and c) direct 
scavenging of reactive oxygen and nitrogen species (76) .   148
Clinical studies in situations associated with oxidative stress such as cardiac I/R(76) 
and acute renal failure from contrast media(380) have shown protective effects with 
NAC administration.  
In liver graft preservation for transplantation using NAC alone(408)or in 
combination with Prostaglandin E1 have shown reduced peak serum ALT levels with 
shorter hospital stay and reduced severity of rejection episodes in the treatment group 
as opposed to control group(39). Experimental work studying the effect of NAC in 
warm I/R injury has shown promising results(132;134;145;221;381).Experimental 
studies have shown that NAC inhibits the stimulated increase in ICAM-1 and 
VCAM-1 expression on endothelial cells in vitro(262;317) and leukocyte – 
endothelial interactions in rat liver transplantation(232;278). A clinical study by 
Weigand et al, in patients who underwent Orthotopic liver transplantation showed 
that NAC administration attenuated the increase in circulating ICAM-1 and VCAM-
1 24 hrs after reperfusion of the donor liver(408).  
In liver transplant patients, increased expression of ICAM-1 in the liver is implicated 
in allograft rejection(1;2) and it is possible that attenuation of the postoperative 
increase in ICAM -1 expression by NAC exerts protective effects with respect to 
longer –term graft survival.  
There are no clinical studies published to evaluate this effect of NAC in patients 
undergoing liver resection. A pilot prospective randomised trial was designed to 
evaluate the effect of NAC on liver function following liver resection and on ICAM-
1 expression. Sample size calculation was based on achieving a 50% reduction in 
ICAM-1 in NAC treated subjects. To demonstrate such a difference with 80% power 
at the 5% level, 15 subjects in each group were required.   149
ICAM-1 was used to power the study since;  
1)  This was a pilot study, hence the use of a very sensitive endpoint to reduce 
patient numbers required for the trial. 
2)  Elevated ICAM-1 expression has been shown to promote junctional and 
nonjunctional transendothelial migration across inflamed vascular endothelium 
(431) (423). 
3)  Previous experimental work has shown that NAC inhibits the stimulated 
increase in ICAM-1 and VCAM-1 expression on endothelial cells in 
vitro(262;317) and leukocyte – endothelial interactions in rat liver 
transplantation(232;278), and also attenuated the increase in circulating ICAM-
1 and VCAM-1 24 hrs after reperfusion of the donor liver(408).    150
8.2: Patients & Methods: 
8.2.1: Patients and Consent 
Sequential patients with resectable liver cancers over a 2 year period were recruited 
into the trial. The study was approved by the local ethical committee and all patients 
gave written informed consent to participate in the study. 
8.2.2: Randomisation issues 
Randomisation was by computer generated list with treatment groups concealed in 
opaque sealed envelopes and the randomisation code was not known to patients or 
investigators (including the entire clinical team involved in patient care) until the 
study was finished. Randomisation was carried out by the Pharmacy department 
(Royal Free Hospital) and infusions were prepared on a named patient basis for the 
trial purposes and all infusions were labelled for NAC trial. Patients were 
randomized to receive NAC (Parvolex
®; Medeva Pharma, Ashton-under-Lyne, 
Lancashire, UK), as an iv infusion (150mg/kg in 250mls of 5% dextrose loading dose 
at the beginning of the operation, followed by 50mg/kg in 500mls of 5%dextrose 
over 4 hours and 50mg/kg in 500ml of 5% dextrose over 8hours) or a placebo 
(equivalent volume of 5% dextrose) over the same time.  
8.2.3: Resection Procedure: 
All patients underwent resection under the care of one primary surgeon (BRD) with 
the same anaesthetic team. All patients received epidural infusion for analgesia, large 
bore central lines for IV access and arterial line for intraoperative monitoring. All 
patients received 1 litre of crystalloid at induction and intraoperative fluid 
administration was adjusted to maintain a urine output of ≥ 1ml/kg/hr. 
All resections were performed with complete liver mobilisation appropriate to the 
planned resection after assessment with intraoperative US scan and preoperative 
staging scans. Inflow to the proposed resection segments was divided prior to   151
parenchymal division. Parenchymal division was performed with CUSA
® 
(Valleylab
©, TYCO Healthcare, Hampshire, UK) and meticulous haemostasis was 
achieved by suture ligation and diathermy of hepatic arterial & venous branches. All 
patients had low CVP (≤5mm Hg) anaesthesia at time of parenchymal division and 
inflow occlusion was not routinely used during parenchymal division. Intraoperative 
transfusions were avoided unless the haematocrit was ≤ 30% and blood products (i.e. 
FFP and Platelets) were transfused as guided by intraoperative assessment of 
coagulopathy by thromboelastography (TEG)(161). 
8.2.4 Clinical end points  
All patients had full blood count, renal function and liver function tests including 
coagulation profile prior to the surgery, just prior to parenchymal division, at the end 
of the operative procedure and daily up to 9
th day postoperatively.  Demographic 
data, blood loss, transfusion requirements, serum lactate levels (lactate-1= immediate 
preoperative, lactate-2=just prior to parenchymal resection, and lactate-3= at end of 
resection), and postoperative morbidity and mortality data were also recorded. 
8.2.5: Immunohistochemistry for ICAM-1 
Protocol liver biopsies were obtained with a trucut needle from the future liver 
remnant upon laporotomy prior to liver mobilisation or handling( biopsy-1) and the 
second protocol biopsy was procured at the end of the operation from the same lobe 
of the remnant liver (biopsy-2). 
Biopsy samples were put on Optimum cutting temperature (OCT
TM) (Tissue-Tek
®, 
Sakura Finetek, Berkshire, UK) covered cork, snap frozen in isopentane and then 
liquid nitrogen and stored at -80° until further analysis. Frozen sections of a 
thickness of 5 microns were cut using a standard cryostat. 
Each section was placed on PLL coated slides, air-dried for 1 hour and then fixed in 
acetone at room temperature for 10  minutes. Blocking of endogenous alkaline   152
phosphatase (addition of levamisole to the Vector Red chromagen) and non-specific 
binding of protein was carried out by covering sections with normal rabbit serum 
diluted 1/10 in Phosphate buffered saline(PBS) for 20 minutes at room temperature. 
Sections were incubated with primary antibody (ICAM-1 (CD54) mouse monoclonal 
antibody, Novocastra, UK) for 1 hour at room temperature (dilution 1:800). Sections 
were washed with PBS and incubated with rabbit anti mouse antibodies (DAKO, Ely 
Cambridgeshire, UK) diluted 1:25 in PBS for 30 minutes in a humidity chamber. 
Sections were washed in buffer and covered with mouse APAAP (DAKO, Ely 
Cambridgeshire, UK) diluted 1:25 in PBS for 30minutes. Sections were developed 
with freshly prepared Vector red chromagen for 10 minutes, washed in PBS and then 
running water, counterstained with Mayer's haematoxylin, differentiated in 0.5% acid 
alcohol, dehydrated, and mounted in synthetic mountant. 
Endothelial cells in capillaries of muscularis propria of intestinal wall were used as 
positive control. Sections stained without the primary antibody was used as negative 
controls. All samples were run in duplicate with positive and negative controls for 
each batch to reduce inter/intra assay variability. This method of ICAM-1 assessment 
has been reported previously and validated (104-106). 
The histological examination was carried out by a pathologist (AQ) without 
knowledge of the treatment group or whether the individual biopsy was pre or post 
resection. The distribution of ICAM-1 staining was assessed in terms of: 1) staining 
of endothelial cells (sinusoids and portal vein endothelium), Kupffer cells, 
hepatocytes, bile duct epithelial cells and lymphocytes; 2) in terms of pattern of 
sinusoidal endothelial cells staining (i.e. patchy when sinusoids staining for ICAM-1 
alternated with sinusoids not staining for ICAM-1 in the same lobule. Diffuse when 
all sinusoids in the same lobule stained for ICAM-1). Diffuse staining in one lobule 
with negative staining in an adjacent lobule was considered as a technical artefact   153
and staining was repeated. The intensity of sinusoidal staining was assessed using a 
semi quantitative grading system adapted from Kiuchi et al.(219), as shown in   
table 8.1. 
Table 8.1: Grading system for ICAM-1 expression 
 
 
Endothelial ICAM-1 was regarded as up regulated in the post-resection biopsy if:  
1)  The pre-resection biopsy showed no staining, and the post-resection biopsy 
  showed staining of any degree; 
  2)  If the pre-resection biopsy showed grade 1 staining and the post-resection 
  biopsy showed grade 3 staining;  
3)  If the pre-resection biopsy showed patchy staining and the post-resection 
  biopsy showed diffuse staining.  
Conversely, endothelial ICAM-1 was regarded as down regulated in the post-
resection biopsy if:  
1)  The pre-resection biopsy showed staining of any degree, and the post-resection 
  biopsy showed no staining; 
2)  If the pre-resection biopsy showed grade 3 staining and the post-resection 
  biopsy showed grade 1 staining; 
3)  If the pre-resection biopsy showed diffuse staining and the post-resection 
  biopsy showed patchy staining. 
Grade Intensity  of  staining 
Grade 0  No staining/expression on endothelium or hepatocytes 
Grade 1  Weak immunostaining only identifiable at high magnification (40x) 
Grade 2  Thin staining/expression on endothelium and scarce expression on 
hepatocytes 
Grade 3 
Thick staining/expression on endothelium and on hepatocytes 
membrane with or without cytoplasm ( “blurred”/ “honey comb” 
pattern)   154
We chose a difference of two points in intensity of staining as evidence of up or 
down regulation, in order to avoid overlap between semi quantitative categories due 
to the subjective nature of this assessment.  
8.2.6: Statistics 
The non-parametric Mann-Witney U test was used for comparison between the 
groups at each time point. Also, the postoperative values at different time points for 
ALT and ALP were added together for intergroup comparison. Data are presented as 
median (range) and p < 0.05 was considered significant. Comparison of proportions 
was used to analyse ICAM-1 results.   155
8.3 Results 
8.3.1 Clinical outcome:  
43 patients were recruited to the trial; however 12 patients were excluded since they 
had inoperable tumours at laporotomy. Of the remaining 31 patients 16 were 
randomised to the placebo group and 15 were randomised to the NAC group. The 
case mix of the two groups and their demographic data is depicted in table 8.1. The 
largest diagnostic categories in both groups were colorectal liver metastases. All 
patients with synchronous liver metastases had preoperative adjuvant chemotherapy 
and these patients underwent liver resection at least 2 weeks following their last 
cycle of chemotherapy. The two groups were well matched and there were no 
differences in age, sex, or case distribution (Table8.2). 
 
Table 8.2:   Case Mix and demographic data of the patients in the two groups of 
the trial 
 
 
 
Diagnosis  Placebo Group 
(n=number) 
NAC Group 
(n=number) 
Colorectal liver  metastases  13 (n=6 synchronous 
metastases 
12 (n=8 synchronous 
metastases) 
Hepatocellular carcinoma  2  2 
GI stromal cell tumour  1  0 
Cholangiocarcinoma 0  1 
Total 16  15 
Age (mean+/- SD)  59±14  64±14 
M:F ratio  1.8: 1  1.5:1   156
There were no significant differences in morbidity or mortality between the groups. 
The overall morbidity was 25% and there were no deaths in the first 30 days 
postoperatively in either group (Table 8.3). There were no significant differences in 
blood loss, transfusion requirements and serum lactate levels between the groups 
(Table 8.3).  
  
Table  8.3:  Morbidity, Mortality, perioperative blood loss, transfusion 
requirements, and serum lactate levels within the 2 groups 
 
 
 
ns = not significant 
*Serum Lactate-1= Lactate levels at start of operation prior to liver mobilisation
 
†Serum Lactate-2= Lactate levels just prior to parenchymal transection 
‡Serum Lactate-3= Lactate levels at the end of operation 
  Placebo Group 
(n=16)  NAC-group (n=15)  p-value 
Morbidity  25% 27%  ns 
Mortality ( 30 day )  0% 0%  ns 
Blood Loss (in mls)  3200+/-1700 
 
2282+/-1387 
  ns 
Blood (units transfused)  4.2+/-2.35 
 
3.21+/-2.8 
  ns 
Fresh frozen plasma 
(units transfused) 
3.0+/-1.83 
 
3.79+/-3.6 
  ns 
Platelets 
(units transfused) 
0.2+/-0.4 
 
0.3+/-0.6 
  ns 
Serum Lactate-1
*  1.51+/-.60 
 
1.99+/-0.73 
  ns 
Serum Lactate-2
†  2.26+/-.80 
 
3.27+/-1.60 
  ns 
Serum Lactate-3
‡  2.62+/-.9 
 
3.66+/-1.26 
  ns   157
Similarly there were no significant differences between the 2 study groups as to the 
extent of liver parenchyma resected (Table 8.4). We did not routinely use the 
pringle’s manoeuvre during parenchymal resection. There were only 2 patients in the 
NAC group and only 1 patient in the placebo group where we used Pringle’s 
manoeuvre. The inflow occlusion was for a total duration of 40 minutes with 
intermittent reperfusion for 10 minutes for each patient respectively.  
 
Table 8.4:  Extent of liver resection within the 2 trial groups 
Extent of Liver 
Resection  Placebo group (n=number)  NAC group (n= number) 
Right/left Hepatectomy  5  4 
Extended Right 
Hepatectomy  2 4 
Wedge resection (2≥ 
segments)  5 5 
Wedge resection single 
segment  4 2 
Total 16  15 
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8.3.2 Liver Function 
Serum Alanine amino transferase (ALT): 
ALT values in the NAC group were lower compared to the placebo group for the 
whole postoperative period (Fig 8.1). This difference was significant at 24 hours 
(p=0.04) and 48 hours postoperatively (p=0.027). The added ALT values of all 
postoperative days were also significantly lower in the NAC group (p=0.001). 
 
Figure 8.1: Serum alanine transaminase 
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* = p<0.05; NACG v/s Placebo   159
 
Serum Alkaline Phosphatase (ALP)  
ALP values were consistently higher in the NAC group for the whole postoperative 
period studied (Fig 8.2). This difference reached significance in the 9
th postoperative 
day (p=0.05). The overall serum ALP values for the entire postoperative period was 
significantly higher in the NAC group (p=0.003). 
 
Figure 8.2: Serum alkaline phosphatase 
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* = p<0.05; NACG v/s Placebo   160
8.3.3 Immunohistochemistry for ICAM-1 
ICAM-1 was expressed predominantly in sinusoidal endothelial cells and Kupffer 
cells. The different grades of ICAM-1 expression are depicted in fig 8.3. There was 
no change in ICAM-1 expression, between the pre & post resection biopsies in 10/16 
patients in the Placebo group and 11/15 patients in the NAC group (using the semi 
quantitative criteria described in methods) 
 ICAM-1 up regulation was observed in 6/16 patients (38%) in the placebo group and 
in 3/15 patients (20%) in the NAC group. ICAM-1 down regulation was observed in 
1/15 patients (7%) in the NAC group and none in the placebo group. These 
differences were not statistically significant (p>0.05).     161
Fig.8.3: Immunohistochemistry showing ICAM-1 Expression 
Light microscopy (400x) stained with Meyer’s haematoxylin (blue background 
counter stain) and immunohistochemistry for ICAM-1 (bright pink stain) showing no 
ICAM-1 (a), Patchy ICAM-1(b) and Diffuse ICAM-1 (c). 
 
a) No ICAM-1 expression 
 
 
 
b) Patchy ICAM-1  
 
 
 
c) Diffuse ICAM-1 
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8.4 Discussion 
The present study has evaluated the use of NAC in preventing I/R injury during liver 
resection surgery. Treatment with NAC was shown to reduce I/R injury, with a 
reduction in hepatocellular injury being evident by 24-48 hours post operatively. 
This is the first time that such observation has been made in humans in this clinical 
setting. However, there was no reduction in any clinically relevant end points such as 
morbidity, mortality, intraoperative or postoperative transfusion requirements. NAC 
infusion was associated with reduced serum ALT levels, higher ALP levels and with 
a trend towards less up regulation of ICAM-1 during the immediate postoperative 
period. 
NAC is a thiol containing compound which scavenges free radicals by nonenzymatic 
reactions. In high concentration it can protect cells by it’s direct antioxidant action 
and also by replenishing the intracellular glutathione stores(76;408). It is ideally 
suited for clinical use due to its ease of availability, low cost, ease of administration 
and limited side effect profile. 
8.4.1: Serum ALT 
Serum ALT is a  cytosolic enzyme and a marker of the severity of hepatocellular 
injury (134;145;160;291;292).
  ALT is more liver specific, reflects the loss of 
hepatocyte membrane integrity and release of cytoplasmic content into the 
circulation and is a useful marker of global liver function(149;198;242). In a 
prospective clinical trial with patients who underwent Orthotopic liver 
transplantation, NAC administration significantly reduced the rise in α-glutathione S-
transferase and decreased peak ALT levels after reperfusion of the donor liver (408). 
We observed a similar reduction in peak serum ALT at 24- 48 hours postoperatively 
in patients who received NAC.   163
8.4.2: Serum ALP 
Serum ALP levels dropped in both groups during the first 24-48 hours 
postoperatively with a gradual increase afterwards. Similar pattern has been observed 
in other studies following liver resections, where persistent increased levels have 
been found 8-12 weeks after the operation(396;397) (367). Serum ALP levels were 
higher in the NAC group compared to placebo group for the whole postoperative 
period. This difference reached significance in the 9
th postoperative day. Serum ALP 
levels are surrogate markers of liver regeneration (112;367;396;397) and hence the 
significant  difference found in our study suggests that NAC may enhance liver 
regeneration.  
8.4.3: Effect of NAC on ICAM-1 expression.  
In our study, although the differences found in ICAM-1 expression were not 
statistically significant, there was still a suggestion that NAC subjects showed less up 
regulation. The lack of statistical significance could be due to the relatively small 
number of patients investigated and the semi-quantitative nature of the technique 
used. Hence, these results should be validated by an additional quantitative method 
of ICAM-1 measurement such as PCR from tissue biopsies. Using a two point 
difference in ICAM-1 staining intensity as evidence of up or down regulation, no 
difference was noted between the NACG & placebo group. This could be explained 
by the constitutional expression of ICAM-1 by sinusoidal cells in normal conditions 
and it’s further induction in acute or chronic liver disease(219).   
All patients in our study were resected for either primary (one patient with HCV 
infection) or secondary liver tumours. The largest group included colorectal cancer 
with liver metastases and 6/16 and 8/15 patients in placebo and NAC group received 
preoperative chemotherapy. Although the biopsies were taken from “normal 
appearing” future liver remnant,  preoperative chemotherapy may have induced   164
ICAM-1 in the baseline biopsies making it more difficult to assess ICAM-1 
expression in response to I/R injury due to surgical intervention alone (202;406).    165
8.5 Conclusion 
The results of the present study suggest a trend towards reduced liver injury when 
NAC is administered prophylactically during liver resection. In order to see if this 
effect can be translated to clinically relevant endpoints a large scale randomised trial 
would be required.  
The pathophysiology of hepatic I/R injury is multimodal and complex(247). 
Although free radical induced injury is an important damaging mechanism in liver 
I/R, it is unlikely to be the primary or sole mechanism of injury(320;340). Evidence 
of beneficial effect of NAC from related but essentially different clinical situations 
should be carefully extrapolated to liver resection surgery(357;380). 
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Chapter 9 
Summary and Conclusion   167
This thesis examines the pathophysiological changes related to Liver IRI in two 
different settings;  
1)  The role of Glycine a non essential amino acid in an in vivo established 
experimental animal model of partial lobar liver IRI and  
2)  Role of antioxidant NAC within a propectively randomised clinical trial. 
9.1: Summary of main findings 
1)  Administration of glycine did not affect the systemic haemodynamic 
parameters in this particular animal model. 
2)  A single dose of intravenous glycine produced sustained amelioration of liver 
IRI up to 6 hours post reperfusion. 
3) Glycine  administration  improved portal blood flow and hepatic 
microcirculation as evidenced by the LDF data. 
4)  Intracellular tissue oxygenation and mitochondrial activity were preserved by 
the single intravenous dose of glycine and this effect was maintained up to 6 
hours post reperfusion. 
5)  Glycine ameliorated the cytokine surge following reperfusion and this effect 
was maintained up to 4 hours post reperfusion on TNF-α and up to 6 hours post 
reperfusion on IL-8 expression. TNF-α is one of the key cytokines released by 
activated KC’s which plays a central role in liver IRI. Reduction in levels of 
TNF-α would be suggestive of direct KC inhibition. Suppression of IL-8 surge 
is even more interesting since it would down regulate the subsequent 
neutrophils recruitment and activation and hence further reducing cellular 
injury. 
6)  Serum AST and ALT are cytosolic markers of severity of hepatocellular injury 
and the sustained reduction of these enzymes post reperfusion, lends further 
credence to the cytoprotective effect of glycine in liver IRI.   168
7)  Glycine administration significantly improved the bile flow post reperfusion 
and this effect was sustained throughout the reperfusion period studied in this 
experimental model. Bile secretion is a useful marker of early liver function 
following transplantation and is considered to be a primary indicator of liver 
function and recovery following IRI in both experimental and clinical studies 
of liver IRI.  
8)  This is the first time that 
1HNMR analysis has been applied to study bile 
composition following glycine administration in a controlled experimental 
model of liver IRI. A rise in bile acid secretion in the glycine treated animals is 
suggestive of early recovery of metabolic activity. Along with this reduced 
lactate levels and phosphatidylcholine levels following reperfusion in the 
glycine treated animals would be suggestive of hepatocellular protection. These 
changes are mirrored by increase in post reperfusion levels of biliary glucose 
and pyruvate suggesting an increased metabolic activity due to conserved 
cellular energetics in the glycine treated animals. The increase in acetate and 
acetoacetate levels of bile in the glycine treated animals is again suggestive of 
early attempt at utilising alternative sources of ATP and conserved cellular 
bioenergetics in this group. 
9.2: Methodological considerations  
9.2.1: The animal model 
The experimental model used in this study allows the assessment of both the 
haemodynamic and functional parameters in the rabbit liver, both under normal 
conditions and when subjected to ischaemia and reperfusion. The sham group 
simulates the effect of prolonged anaesthesia on the liver and other haemodynamic   169
parameters while the control group (I/R alone) simulates ischaemia reperfusion as 
encountered during liver transplantation/resectional surgery. 
The rabbit was primarily selected for its size, to allow us to study the reperfusion 
phenomenon in a continuous fashion, within the same animal model and allow 
multiple samples at sequential time intervals without significantly compromising the 
haemodynamic stability of the model and simulating the clinical scenario of 
resectional surgery/transplantation. The other advantages being resistance to surgical 
trauma and infection, advantage of size and liver anatomy which makes the technical 
procedure possible and the availability and relative economy of maintenance. 
The anatomy of the rabbit liver with separate lobes makes it easy to identify the 
vascular elements thus allowing for selective interruption of the blood supply. This 
model offers a well defined volume of liver tissue that can be rendered ischaemic 
with little or no alteration of systemic haemodynamics. In this model lobar Ischaemia 
was induced by clamping the vascular pedicles of the median and left lobes of the 
liver, using an atraumatic microvascular clip. This method produces a severe 
ischemic insult without inducing mesenteric venous hypertension(134;145). During 
the occlusion period the right lateral and caudate lobes are not subjected to ischaemia 
thereby accommodating the splanchnic blood flow without major changes in portal 
pressure. This allows the study of small changes in liver vascular bed due to 
ischaemia reperfusion. Since the portal blood flow is not totally interrupted 
haemodynamic stability of the model is maintained. The time points studied in these 
experiments were selected on the basis of previous experimental evidence which has 
shown consistent time related changes in the post reperfusion blood flow and thus 
provide a sensitive indicator of any beneficial or adverse drug effects. The model is 
easy to establish and reproducible; the initial ischaemic changes in the liver are 
evident and leave no doubt as to the correct positioning of the clamp.     170
An important criticism of this particular animal model has been that it does not 
simulate the clinical conditions of total liver ischaemia, which occurs in liver 
transplantation or during periods of inflow occlusion (Pringle’s manoeuvre) 
encountered during liver resections. Previously Kanoria et al have demonstrated that 
total hepatic ischaemia is poorly tolerated by rabbits, resulting in severe metabolic 
acidosis and cardiac arrest due to severe hypotension(203). Besides acute portal 
venous occlusion causes mesenteric venous congestion leading to compromise of the 
intestinal mucosa with bacterial translocation predisposing to systemic inflammatory 
response syndrome(225). In the rabbit model of partial liver IR used in these 
experiments only the blood flow to the medial and left lobes was interrupted leaving 
the right and caudate lobes with normal circulation. The partial lobar ischaemia 
allows splanchnic blood flow, preventing the haemodynamic instability due to 
mesenteric venous congestion and portal bacteraemia found in the total inflow 
occlusion model(225). 
The normothermic lobar ischaemia simulates to an extent the circulatory and 
metabolic conditions of transplantation, which is simple, robust and reproducible 
with low mortality. The animal liver transplant model as opposed to the in vivo 
model used in this study, involves organ harvest and preservation at low 
temperatures with the technical difficulty of re-establishing portal and arterial blood 
flow, organ dennervation and artefacts due to organ cooling with the possibility of 
immunological involvement which renders significant complexity to the liver 
transplant model. One of the major limitations of the model is that it is not 
appropriate for recovery and thus cannot assess the effect of glycine during the latter 
phases of liver IRI.   171
9.2.2: Laser Doppler Flowmetry (LDF) 
Study of the hepatic microcirculation is of major pathophysiological significance in 
any strategy to reduce/ameliorate IRI. Microcirculatory changes correlates well with 
the degree of liver IRI(402). LDF used in the present study assessed the 
microcirculation directly and the depth of penetration was adequate since the 
maximum thickness was less than 10mm. LDF however, is a reflection of the local 
changes in the liver and does not measure microcirulatory blood flow of the whole 
liver. The LDF probe was applied to a fixed point throughout the experiments 
allowing continuous record of the local changes in microcirculation. Previously 
Seifalian  et al have reported a coefficient of variation of  4% at intersite LDF 
measurements(336;337). This would suggest that measurements of local 
microcirculatory changes would be reflective of the entire affected lobe and surface 
LDF measurements would be representative of deep parenchymal perfusion(337).    
Motion artefact due to vibration or probe movement was attempted to be minimised 
by deeper anaesthesia, with good liver mobilisation and placement of the probe such 
that it allowed the whole liver and probe to move simultaneously as one unit. 
The value of blood flow measured was expressed in flux units. A baseline recording 
of flow as a standard (100%) was used in each individual experiment. The amount of 
back scattered light varies from one organ to another depending on factors like light 
absorption and red cell fraction of different tissues. It is not possible therefore to 
translate the values into a unit of flux which can be utilised as standard for different 
organs. However, when applied to the same organ the signal is reproducible within a 
narrow range of variation. LDF is now a well recognised and extensively validated 
technique for estimation of liver blood flow.   172
9.2.3 Near Infra red Spectroscopy (NIRS) 
NIRS is a non-invasive technique to assess mitochondrial activity and cellular energy 
production (101;145). Seifalian and El-desoky et al  have validated the measurement 
of  cytochrome oxidase(CytOx) against other techniques(101;102) such as nuclear 
magnetic resonance spectroscopy and partial oxygen pressure. Bright operating lights 
interfered with the measurements and hence the probes were shielded with lightproof 
black cloth. Variations in measurements with reapplication even on the same site 
meant that the probes must be applied and maintained in the same site during the 
whole procedure which is impractical in a clinical scenario. In the present study 
recording of CytOx  data was unaffected from the reapplication of probes and 
accurately represented the redox state of the enzyme which correlated with the LDF 
data, cytokine and transaminase measurements as well as changes in bile 
composition, this has been shown previously by Glantzounis et al (145). 
9.2.4 Bile Proton Nuclear Magnetic Resonance (
1HNMR) spectroscopy 
Bile flow and changes in bile composition demonstrated by preconditioning with 
glycine provides evidence to the cytoprotective effects of glycine against liver IRI. 
These changes in bile composition by preconditiong with glycine have not been 
reported previously. The quantitative data provides robust data compared to the other 
endpoints wherein the measurement of change was relative to the baseline. This 
technique may be helpful in the postoperative assessment of early liver graft 
dysfunction.  In the animal model used bile was specifically collected for 
1HNMR 
spectroscopy measurements, however in clinical setting of liver transplantation 
unless a T-tube is used for biliary anastomosis or alternatively bile is collected by 
other means, this technique may be difficult to apply clinically routinely.   173
9.2.5 Cytokine measurements 
 KC activation appears to be the primary event which sets the liver IRI cascade into 
motion. Hepatic I/R injury is initiated by activation of KC in the liver during 
Ischaemia (192;194;348). However it is the cytokine release by these activated KC 
which plays a pivotal role in the inflammatory response during hepatic IRI 
(72;192;251). Tumour necrosis factor alpha (TNF) and interleukin-1 (IL1) are the 
key cytokines which are produced by activated KC and are most commonly 
implicated in hepatic IRI (15;71;369). These two cytokines in turn induce IL-8 
synthesis, which initiates the late phase of liver IRI (71;192). Since glycine directly 
prevents KC activation measurement of serum TNF-α would be a direct reflection of 
the extent of amelioration of the IRI by the administered glycine. The ELISA 
provides robust quantitative data and a technique which is easily reproducible within 
a short period of time. This technique can be easily extended into clinical practise 
since ELISA kits for various cytokines are readily available for clinical use. The 
increase in serum  TNF-α levels in the I/R+Glycine group at the 6
th hour following 
the ischaemic episode would suggest that the protection conferred by a single 
intravenous dose would last for up to 4 hours. These results are consistent with 
previously reported studies on half life of glycine in circulation (155). The only 
difficulty with the TNF-α ELISA was the primary and detecting antibody 
concentrations had to be optimised prior to use. 
IL-8 ELISA was straightforward and easily reproducible since it was a commercially 
available kit with pre optimised paired monoclonal antibodies. Sustained significant 
reductions in IL-8 levels would lend credence to the cytoprotective effects of glycine 
and this has not been reported before. Since IL-8 is responsible for neutrophil   174
recruitment and the late phase of liver IRI amelioration of this key cytokine would 
suggest further reduction in the severity of the liver IRI. 
9.2.6 Liver transaminases 
The quantitative assessment of liver function remains a problem because of the 
complexity of the multiple metabolic and excretory functions of the liver. Liver has a 
significant functional reserve which allows it to sustain significant damage without 
evidence of metabolic derangement. 
Indocyanine green clearance and rate of urea synthesis have been proposed as 
quantitative function test. Serum levels of bilirubin, transaminases and alkaline 
phosphatase are measured easily and available widely. Alanine aminotransferase 
(ALT) occurs virtually in the liver while aspartate amino transferase (AST) occurs 
partly in the liver. These enzymes are present in the hepatocyte cytoplasm and thus 
provide valuable information regarding the extent of hepatocyte damage. The amount 
of intracellular enzyme released into the plasma is an index of the integrity of the cell 
membrane and hence indirectly of damage to hepatocytes. These enzymes and their 
levels however, cannot give information about the function of viable living liver 
cells. 
9.3 N-acetylcysteine in patients undergoing liver resection 
The use of NAC within a clinical trial allows us to study and translate the 
experimental benefits of an antioxidant to a clinically safe and relevant scenario. A 
double blind randomised trial incorporating a placebo arm is the gold standard for 
studying the effects of a drug in a clinical setting. All relevant permissions and 
consents were obtained prior to recruitment. Both the patient and the observers were 
blinded using computer generated non sequential numbers. The blinding was 
removed only after all endpoints were assessed and the trial completed.   175
Randomisation was done by the department of inpatient pharmacy who had no 
clinical contact with the patients recruited for the study.  Recruitment to the trial was 
voluntary and the trial protocol was approved by the local ethics committee. 
The power calculations were done by the hospital statistician (Dr Morris). Due to 
ethical constraints trucut liver biopsies were only performed during the actual 
operation, since the risk associated with elective liver biopsies postoperatively 
following major liver resection was considered too high. 
The following difficulties were encountered during the trial. First of all the primary 
endpoint was ICAM-1 expression following surgery in trucut liver biopsies which 
were snap frozen in liquid nitrogen. Although all the biopsies were considered to be 
adequate there were artefacts encountered due to air bubbles incorporated in the cryo 
glue used for snap freezing. This was tackled by careful technique and improved 
handling of the biopsy specimen. 
The other confounding factor was semi quantitative nature of the ICAM-1 as 
evaluated by immunohistochemistry. In some specimens the baseline ICAM-1 was 
upregulated which might be due to the preoperative chemotherapy or concomitant 
viral infections (hepatitis B/C) thus making it difficult to adequately assess up 
regulation following liver resection. The first biopsy and the second biopsy were 
both performed from the same remnant liver, but for more robust evaluation the 
second liver biopsies should be obtained 12-24 hours post resection. These reasons 
could explain the lack of statistical significance with regards to ICAM-1 expression. 
Despite these shortcomings there was a trend towards reduced ICAM-1 up regulation 
in the NAC treated group. Recruiting larger numbers of patients might also help in 
elimination of this problem. Both the patient groups were well matched for age, sex, 
number of segments resected and type of resections performed with comparable 
morbidity and mortality. Serum ALT levels were significantly attenuated in NAC   176
treated group while the serum alkaline phopsphatase a marker of bile duct 
regeneration post liver resection was significantly higher in the NAC treated group. 
This would suggest that NAC did confer protection within these groups of patients. 
This is the first trial of its kind using NAC in patients undergoing elective liver 
resections with a trend towards support for use of NAC in complex liver resections.  
9.4 Future Studies 
1)  There is enough experimental evidence both in this thesis and in the literature 
to support the prophylactic use of glycine in liver resectional surgery and 
transplantation to prevent IRI. It would be very interesting to see the effect of 
this molecule in a randomised clinical trial involving liver 
resection/transplantation. In liver transplantation it should be given to donors 
prior to organ procurement as a single intravenous dose and to organ recipients 
it can be administered twice a day initially till patients are resumed on oral 
feeds and can then be administered orally for the first week following surgery. 
2)  NAC is a very useful antioxidant and although the clinical trial in this thesis 
showed a trend towards improved liver function, a large scale multicentre 
randomised controlled trial would be required to achieve a significant 
difference in the clinically relevant outcomes. 
3)  Since KC and ROS are the two key factors involved in initiation and 
propagation of liver IRI combining NAC and glycine may prove to be pivotal 
in ameliorating IRI almost completely. This hypothesis has not been 
investigated before. 
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Presentations and publications from the thesis 
Presentations: 
1)  A randomised double blind controlled clinical trial to assess the effects of 
prophylactic N-Acetylcysteine on liver injury during liver resection,  
H Sheth, G Glantzounis, T Hafez, A Quaglia, J Duncan, B R Davidson, 
presented as a free paper at the Society of Academic and Research Surgery 
(SARS) held in January 2005 at Newcastle, UK. 
 
2)  Glycine suppresses cytokine expression and improves bile flow in a rabbit 
model of liver warm ischaemia-reperfusion injury,  H Sheth, T Hafez, 
G Glantzounis, K M Sales, A Seifalian , B Fuller, B R Davidson, presented as a 
free paper at the  Society of Academic and Research Surgery (SARS) held in 
January 2005 at Newcastle, UK. 
 
3)  Bile flow and composition are modulated by intravenous glycine in an in-
vivo warm ischaemia-reperfusion injury model: T Hafez, H Sheth,  
G Glantzounis, H G Parkes, B Fuller, B R Davidson. presented as a free paper 
in the young investigator’s prize session, at the 6
th World Congress of the 
International Hepatopancreatobiliary association, held in June 2004 at 
Washington DC.  
 
4)  Intravenous glycine ameliorates ischaemia reperfusion injury in the rabbit 
liver lobar ischaemia reperfusion model: H Sheth, T Hafez, G Glantzounis,  
A Seifalian, B Fuller, B R Davidson, presented as a free paper at the 6
th World 
Congress of the International Hepatopancreatobiliary association, held in June 
2004 at Washington DC.  
 
5)  Glycine suppresses cytokine expression and improves bile flow in a rabbit 
model of liver warm ischaemia-reperfusion injury:  H Sheth, Hafez T,   
G Glantzounis, K Sales, B Fuller, B R Davidson, presented as a poster at the 6
th 
World Congress of the International Hepatopancreatobiliary association, held 
in June 2004 at Washington DC. 
 
6)  A randomised double blind controlled clinical trial to assess the effects of 
prophylactic N-acetylcysteine on liver injury during liver resection:  
H Sheth, G Glantzounis, Hafez T , A Quaglia, B Fuller, J Duncan,   
B R Davidson, presented as a poster at the 6
th World Congress of the 
International Hepatopancreatobiliary association, held in June 2004 at 
Washington DC.    178
7)  Intravenous glycine ameliorates the early phase of warm ischaemia-
reperfusion injury in a rabbit lobar liver ischaemia reperfusion injury 
model:H Sheth, T Hafez, G Glantzounis, A Seifalian, B Fuller, B R Davidson. 
Presented as a poster at the Society of Academic and Research Surgery (SARS) 
held in January 2004 at Belfast. 
 
8)  Bile flow and composition are modulated by intravenous glycine in an in 
vivo warm ischaemia reperfusion injury model:T Hafez, H Sheth,  
G Glantzounis, W Yang, H G Parks, A Seifalian, B Fuller, B R Davidson, 
presented as a plenary session poster at the British Society of Gastroenterology 
annual meeting held in March 2003 at Glasgow, UK. 
 
9)  Glycine ameliorates the early phase of liver warm ischaemia-reperfusion 
injury in a rabbit model: H Sheth, T Hafez , G Glantzounis, K M Sales, 
  A Seifalian, B Fuller ,B R Davidson, presented as a poster at the British 
Society of Gastroenterology annual meeting held in March 2003 at Glasgow, 
UK. 
 
Publications 
 
1)  Glycine reduces liver warm ischaemia reperfusion injury by improving the 
hepatic microcirculation and enhancing mitochondrial activity : H Sheth, 
T Hafez, G Glantzounis, K Sales, A Seifalian, B Fuller, B R Davidson. 
Accepted for publication by Journal of Hepatology and Gastroenterology 
March 2010. 
 
2)  Acute limb Ischaemia caused by femoral arterial line induces remote liver 
injury in a rabbit model of liver Ischaemia/reperfusion injury:  
G Glantzounis, H  Sheth, C Thompson C, T Hafez, S Kanoria,V Pamecha, 
 S Davies ,D P Mikhailidis, A Seifalian, B R Davidson. Angiology. 2009 Oct-
Nov;60(5):554-61. Epub 2009 Jul 21. 
 
3)  Glycine protects bile physiology and biliary-specific liver cell metabolism 
from Ischaemia-reperfusion injury; a 
1HNMR study: T Hafez, H Sheth,  
G Glantzounis, H Parkes, A Seifalian, B Fuller, and B R Davidson; Cell 
Preservation Technology 6:173–180 (2008). 
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